Synthesis and characterization of new modified metabolites, molecules with strong pharmacological activities by Gravante, Raffaele
UNIVERSITA’ DEGLI STUDI DI NAPOLI 
FEDERICO II 
 
 
Ph.D. Thesis in Chemical Sciences 
XXIX Course 
 
Synthesis and characterization of new modified metabolites, 
molecules with strong pharmacological activities 
 
Raffaele Gravante 
 
Tutor                                                                                        Supervisor 
Dr. Giovanni Di Fabio                                       Dr. Annalisa Guaragna 
 
Coordinator 
Prof. Luigi Paduano 
 
Summary 
Polyphenols are the most widely distributed class of plant secondary metabolites and several 
thousand different compounds have been identified. They play many different roles in plant biology 
and human life, as UV protective agents, defensive compounds against herbivores and pathogens, 
they contribute to plant colors and to the taste of food and drink. Moreover it is widely known that 
natural metabolites have played a crucial role in the identification of many of the drugs that are on 
the market today. Nowadays natural products used pure in pharmacological preparations represent 
only 5% of the total, but their semi-synthesis derivatives represent more than 50% of the drugs in 
use.1 
My PhD project is focused on the chemistry of natural substances, and I developed some strategies 
to synthetize  new silibinin conjugates. Silibinin is the major biologically active component of the 
seeds extract of the milk thistle (Silybum marianum) also known as silymarin.2 Structurally, 
silibinin is a diastereoisomeric mixture of two flavonolignans, silybin A and silybin B in a ratio of 
approximately 1:1 (Figure 1).3 
 
Figure 1 
Silibinin is a metabolite with multiple biological activities operating at various cell levels.4 
Unfortunately, its therapeutic efficiency is rather limited by its low bioavailability due to its very 
low water solubility.  
Aiming to improve the solubility, during the first year of my PhD project, we have developed an 
efficient synthetic procedure to obtain new 9”-phosphodiester silibinin conjugates with different 
mono- and di-saccharide labels through the anomeric hydroxyl group (Figure 2).5 
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Figure 2 
In our approach 9’’-phosphoramidite has been used as silibinin substrate and 1-OH full protected 
mono- and disaccharide derivatives as sugar starting materials. We initially converted full 
acetylated mono and di-saccharides into 1-OH derivatives and these  compounds were coupled with 
9’’-phosphoramidite silibinin. The oxidation and the deprotection treatments led to the desired 
phosphodiester derivatives in good yields. The crude materials were then subjected to the 
purification by reverse phase analysis (RP-18 HPLC), using a variety of columns and elution 
conditions, but unfortunately it was too difficult to purify the mixture of diastereoisomers. In the 
end new silibinin analogues were obtained as a mixture of diastereoisomers, observed by 31P NMR 
analysis. The NMR analysis has proved to be very complex, in fact 1H and 31P NMR spectra of all 
compounds showed a dramatic complexity, due to the presence of a lot of diastereoisomers. This 
drawback has not allowed a complete and detailed NMR characterization of the new derivatives. 
The structures were confirmed by 31P NMR and ESI-MS mass spectra signals. In preliminary study, 
new derivatives were subjected to DPPH free radical scavenging and Xanthine Oxidase inhibition 
assays to evaluate their antioxidant activities. Independently of the sugar moiety present, all 
compounds exhibited a radical scavenging activities slightly higher than that of the silibinin, and 
Xanthine Oxidase inhibition at least as that of the silibinin. On the other hand the new derivatives 
showed a water solubility well above that of silibinin, in fact it was possible to prepare solutions of 
about 70 mg/mL in water.  
These two data encouraged our studies during my second year of PhD to improve this synthetic 
strategy and to realize libraries of optically pure glyco-conjugated silibinins. 
The 9''-phosphoramidite has been used as silibinin substrate and fully protected 6-OH mono- and 
di-saccharide derivatives as sugar starting materials (Figure 3).6 
 Figure 3 
We initially converted opportunely protected mono- and di-saccharides (Glucose, Mannose, 
Galactose, N- Acetylglucosamine, Trehalose and Lactose) into 6-OH derivatives and then they were 
coupled with 9"-phosphoramidite silibinin following typical phosphoramidite chemistry procedure. 
The crude materials were purified by reverse phase chromatography (RP-18 HPLC) and 
characterized by NMR and MALDI- TOF/TOF-MS analyses. All compounds were obtained in 
good yields and as a mixture of two silibinin diastereoisomers (A and B). Finally new 
phosphodiester derivatives were converted into the corresponding sodium salt by cation exchange 
resin carrying crystalline samples. New derivatives showed water solubility well above that of 
silibinin, with the possibility to prepare solutions of about 70 mg/mL in water. The stability of new 
glyco-conjugates was investigated in human serum by HPLC analyses and the 50% disappearance 
of the peak corresponding to the intact glyco-conjugate was observed after ca. 40-68 hours. All 
derivatives were subjected to DPPH free radical scavenging assay and they exhibited radical 
scavenging activities slightly higher than that of the silibinin. In order to verify the potential 
biological properties of these derivatives, a biological assay was used to evaluate the cytotoxicity of 
the new glyco-conjugates, compared with that of the silibinin, on human liver cancer cell line (Hep 
G2). No significant changes in the viability of treated cells were observed when they were subjected 
to the action of glyco-conjugates, also considering the longest incubation (72 hours) at the 
maximum dose taken (30 µM). Also, in order to investigate the role of the different OH groups in 
the antioxidant activity of new glyco-conjugates in comparison with silibinin, their acidity and 
redox capacity have been evaluated. A redox-deep characterization was carried out in collaboration 
with Prof. Mauro Iuliano and Dr Gaetano De Tommaso of our Department, using potentiometric 
and voltammetric techniques. The determination of the acidity constants was conducted by 
potentiometric titrations measuring the concentration of hydrogen ions with a glass electrode. By 
processing data, it was possible to define three equilibrium constants. Analysis of the data shows 
that the conjugation in position 9" does not affect the redox behaviour of the silibinin scaffold. 
As a part of our continuing research effort towards the synthesis of new natural product analogues 
exploiting the phosphoramidite chemistry, in the last year of my PhD project the attention was 
focused on the development of synthetic methods to obtain oligoflavonoids based on silibinin, and 
to investigate their anti-radical activity. Exploiting the selective protection to hydroxyl groups of the 
silibinin we have developed an efficient strategy for the synthesis of new 3-9", 3-3 and 9"-9" dimers 
of silibinin in good yields (Figure 4).7 
 
Figure 4 
In order to obtain suitable building blocks for the dimers synthesis, we have developed a selective 
protective reaction for the different hydroxyl groups with isobutyric anhydride. The building blocks 
obtained were coupled in the three different provisions with 3- and 9”-silibinin phosphoramidite 
using the well known phosphoramidite chemistry. After oxidation, deprotection and RP-18 HPLC 
purification the products were converted into the corresponding sodium salts by cation exchange on 
a DOWEX (Na+ form) resin, leading to the desired phosphodiester dimers derivatives in good 
yields. The structures of new analogues were confirmed by 31P NMR and MALDI-TOF/TOF-MS 
analyses. The stability of new silibinin dimers was investigated in human serum by HPLC analysis 
and the 50% disappearance of the peak corresponding to the intact molecule (t1/2) was observed 
after ca. 80 hours. All derivatives were subjected to DPPH free radical scavenging assay and they 
exhibited activities quite higher than silibinin. 
Moreover, the solubility in water of silibinin and its dimers as well as their ability to react with 
reactive oxygen species (ROS) were determined by estimating their second order rate constant with 
singlet oxygen (1O2) and hydroxyl radical (HO∙) in solution. This data were obtained in the 
laboratories of Prof. Marcello Brigante during my experience work in his research team at the 
University Blaise Pascal, Institute of Chemistry of Clermont-Ferrand (France). Solubility 
experiments indicate that dimers were completely dissolved (0.1 mg in 10 mL) in water and 
solubility can be estimated to be ≥ 19.5 µM corresponding to > 20 mg/L. 
Reactivity between silibinin and dimers with 1O2 and HO∙ was determined by use of Rose Bengal 
(RB) and hydrogen peroxide as respective ROS sources. For this purpose, 545 nm centered 
excitation of RB and laser flash photolysis (LFP) experiments were coupled with a kinetic 
competition approach. Dimers reactivity toward singlet oxygen results to be close to the value 
determined for silibinin, or about 35% lower. Second order rate constant fare in the same order of 
magnitude reported in literature for molecules with similar structure. Morales and co-workers8 
reported a reactivity ranging from 2.4 to 13.4 × 107 M-1s-1 for flavonoid derivative such as quercetin 
and morin. Estimation of second order rate constant reactivity with HO∙ indicates that some dimers 
showed a second order rate constant ≥ 1.5 × 1010 M–1s–1. Wang and co-workers9 investigated the 
reactivity of hydroxyl radical with phenolic compounds in order to estimate their anti-oxidative 
ability using aqueous pulse radiolysis. The value of 1.5 × 1010 M–1s–1 was found for quercetin that is 
close to those estimates for green tea polyphenols. Interestingly, Husain at al.10 reported that 
reactivity of flavonoids toward photo-generated hydroxyl radical increases with the number of 
hydroxyl groups in the aromatic ring. 
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Chapter 1: Introduction 
1.1 Natural products and secondary metabolism 
 
For million years, humankind is completely dependent on plants as source of carbohydrates, proteins 
and fats for food and shelter. In addition, plants are a valuable source of a wide range of secondary 
metabolites, which are used as pharmaceuticals, agrochemicals, flavours, fragrances, colours, 
biopesticides and food additives.  
The secondary metabolites, as the name suggests, are so-called because they are produced by the plant 
secondary metabolism. Primary metabolism refers to the processes producing the carboxylic acids of 
the Krebs cycle, α-amino acids, carbohydrates, fats, proteins and nucleic acids, all essential for the 
survival and well-being of the organism.1 All organisms possess the same metabolic pathways by 
which these compounds are synthesized and utilized. Secondary metabolites, on the other hand, are 
non-essential to life but contribute to the species fitness for survival.1 Secondary metabolites are also 
produced using other metabolic pathways than primary metabolites. These pathways are more 
characteristic for the particular family or genus and are related to the mechanism of evolution of 
species. In fact, the specific constituents in a certain species have been used to help with systematic 
determination, groups of secondary metabolites being used as markers for botanical classification.1 
The division between primary and secondary metabolism is not clear, but the two types are linked 
together because primary metabolism provides the small molecules that are the starting materials of the 
secondary metabolic pathways (Figure 1.1). 
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Figure 1.1 Primary metabolites and their links to secondary metabolism. 
One of the most important families of secondary metabolites is that of polyphenols. Polyphenols are the 
most widely distributed class of plant secondary metabolites and several thousand different compounds 
have been identified. They play many different roles in plant biology and human life, including UV 
protection, defense against herbivores and pathogens, and they contribute to plant colors,  taste of food 
and drink, and are used as pharmaceuticals. 
1.2 Plant polyphenols: molecules with a high degree of molecular diversity 
 
“Eating five servings of fruits and vegetables per day” 
 This is what is highly recommended and heavily advertised nowadays to the general public to stay fit 
and healthy. “Drinking green tea on a regular basis”, “eating chocolate from time to time”, as well as 
“savoring a couple of glasses of red wine per day” have been claimed to increase life expectancy even 
further. Why? The answer is in fact still under scientific scrutiny, but a particular class of compounds, 
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naturally occurring in fruits and vegetables, is considered to be crucial for the expression of such 
human health benefits: the polyphenols.  
1.2.1 A bit of history  
Before being called polyphenols, these plant-derived natural products were globally referred to as 
“vegetable tannins” as a consequence of the use of various plant extracts containing them in the 
conversion of animal skins into leather. The first mentions of vegetable tanning in the classical 
literature are accredited to the founder of the science of botany, Theophrastus of Eressus (371–286 BC), 
in his Historia Plantarum encyclopedia and the origins of this leather-making process get lost in the 
depths of the most ancient records of the history of human civilizations.2  
Over the centuries, “vegetable tannins” have never ceased to garner general (and commercial) interest, 
as well as scientific curiosity,3 and from the beginning of the last century an increasingly numerous of 
chemists got involved in this affair, mainly concerned with finding an accurate method for analyzing 
tanning extracts used in the leather industry. This was indeed a valuable and quite honorable objective, 
but far from trivial given the means of chemical analysis available at the time. Fortunately, over the 
years, botanists, plant physiologists, phytochemists and biochemists, as well as a few obstinate organic 
chemists, kept on studying polyphenols and underlying their significance not only as major and 
ubiquitous plant secondary metabolites, but also as compounds that express properties with numerous 
implications and potential exploitations in various domains of general public and commercial interests. 
So polyphenols gradually became a topic of intensive investigation in various plant-related scientific 
domains, including applied research areas such as agriculture, ecology, food science and nutrition, as 
well as medicine.4,5 The development of more and more advanced analytical techniques that paralleled 
this gradual expansion of interest in polyphenol research during the second half of the past century 
clearly had a major positive impact on both the development of the field and its appreciation by the 
scientific community at large. 
Nowadays, plant polyphenols enjoy an ever-increasing recognition not only by the scientific 
community but also, and most remarkably, by the general public because of their presence and 
abundance in fruits, seeds, vegetables and derived foodstuffs and beverages, whose regular 
consumption has been claimed to be beneficial for human health. It is their capacity to scavenge 
oxidatively generated free radicals, such as those derived from lipids and nucleic acids, that has often 
been highlighted as the fundamental chemical event that underlies their utility in reducing the risk of 
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certain age-related degenerations and diseases. Although this so-called antioxidation property is not 
listed among the qualifying factors that make a plant phenolic a “true” polyphenol, it has become the 
trademark of “polyphenols” in recent exploitations by the agro-food, cosmetic, and parapharmaceutic 
industries. However, antioxidation is not a property limited to polyphenols, as numerous simple plant 
phenols are strong antioxidants, with many of them being in fact used as the active principles present in 
some industrial formulations. The use of the term “plant phenols” by industry would definitely be more 
appropriate, but the term “polyphenols” is preferred for commercial communications. As in the case of 
earlier confusions surrounding the use of the term “tannins” in the scientific literature, the term 
“polyphenols” has been and is still often misused by scientists from industry as well as academia.  
1.2.2 What are plant polyphenols really? 
 
According to a common classification, the polyphenols are divided into several sub-classes, based on 
the number of phenolic rings present in their structure, the structural elements that bind these rings 
between them and to the substituents bound on the rings. On this basis, they can be identified two 
major groups: flavonoids and non-flavonoids polyphenol.6 
x The flavonoids (Figure 1.2), share a structure formed by two aromatic rings, indicated as A and 
B, linked together by three carbon atoms that form an oxygenated heterocycle, the ring C. They 
can be further divided into several subclasses, depending on the type of involved heterocycle : 
flavones, flavonols, flavanones, flavanonols, flavanols or flavan-3-ols or catechins, 
anthocyanins and anthocyanidins, isoflavones, neoflavonoids, chalcones. 
 
Figure 1.2 Basic structure of flavonoids. 
 
x Among the non-flavonoid polyphenols are identified: simple phenol, phenolic acids, benzoic 
aldehydes, hydrolysable tannins, acetophenones and phenylacetic acid, hydroxycinnamic acids, 
coumarin, benzophenones, xanthones, stilbene, lignans, secoiridoids.  
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The above assortment of structure types is admittedly far from providing a clear picture of the family of 
plant polyphenols. Of course, the presence of more than one hydroxy group on a benzene ring or other 
arene ring does not make them polyphenolic. Catechol, resorcinol, pyrogallol, and phloroglucinol (all 
di- and trihydroxylated benzene derivatives) are still defined as “phenols” according to the IUPAC 
official nomenclature rules of chemical compounds7 but many such plant-derived monophenolics 
(Figure 1.3) are often quoted as “polyphenols”, not only in cosmetic, parapharmaceutic, or nutraceutic 
commercial advertisements, but also in the scientific literature, which has succumbed to today’s 
fashionable use of the term.  
 
 
 
Figure 1.3 Examples of simple plant-derived “monophenolics”.  
The meaning of the chemical term “phenol” includes both the arene ring and its hydroxy substituent(s). 
Hence, even if we agree to include polyphenolic compounds with no tanning action in a definition, the 
term “polyphenol” should be restricted in a strict chemical sense to structures bearing at least two 
phenolic moieties, irrespective of the number of hydroxy groups they each bear. However, as 
judiciously pointed out earlier by Jeffrey B. Harborne,8 such a purely chemically based definition of 
(poly)phenols needs additional restrictions, since many natural products of various biosynthetic origins 
contain more than one phenolic unit. The existence of such alkaloids still gives us another problem 
when attempting to define plant polyphenols in an as simple and yet comprehensive manner as possible, 
since the tyrosine amino acid from which they are derived is itself a (primary) metabolite of the 
phenylpropanoid pathway. It isn’t totally surprising by the difficult qualification of these molecules, but 
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the interest that the (poly)phenols plant arouse in various scientific fields requires greater clarity. This 
raises the need to arrive at a revised definition of "real" plant polyphenols, purely chemical mold, 
referring to the biosynthetic process by which they are formed. This definition may be as follows: the 
term “polyphenol” should be used to define plant secondary metabolites derived exclusively from the 
shikimate-derived phenylpropanoid and/or the polyketide pathway(s), featuring more than one 
phenolic ring and being devoid of any nitrogen-based functional group in their most basic structural 
expression. 
This definition leaves out all monophenolic structures, which include di- and trihydroxyphenyl variants, 
but contains three main categories of compounds, that can be identified as "true" polyphenols:  
1. the proanthocyanidins (condensed tannins) such as procyanidins, prodelphinidins, and 
profisetinidins (Figure 1.4), which are derived from the oligomerization of flavan-3-ol units 
such as (epi)catechin, epigallocatechin, and fisetinidol (Figure 1.5).9 
 
 
Figure 1.4 Representative examples of condensed tannins.               
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Figure 1.5 Representative examples of flava/flavonoids. 
 
2. the gallo- and ellagitannins (hydrolyzable tannins), which are derived from the metabolism of 
the shikimate-derived gallic acid (3,4,5-trihydroxybenzoic acid) that leads through esterification 
and phenolic oxidative coupling reactions to numerous (near 1000) monomeric and oligomeric 
polyphenolic galloyl ester derivatives of sugar-type polyols, mainly D-glucose (Figure 1.6),10,11  
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Figure 1.6. Representative examples of hydrolyzable tannins.  
3. the phlorotannins that are found in red-brown algae (Figure 1.7) and essentially derived from 
the oligomerizing dehydrogenative coupling of phloroglucinol (1,3,5-trihydroxybenzene).12 
 
 
Figure 1.7 Representative examples of phlorotannins. 
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1.3 Poliphenols: focus on the antioxidant activity 
 
There are numerous reasons to investigate plant polyphenols. From their most basic structural 
expressions to their elaboration into further chemically transformed and complex oligo/polymeric 
assemblies, plant polyphenols exhibit a remarkably diverse range of bio-physicochemical properties 
that makes them rather unique and intriguing natural products. The first question that comes to mind is 
why did plants choose to rely so heavily on the production of metabolites with multiple phenolic 
moieties. The answer to this question is still a subject of debate and speculation, and possibly differs 
for the different types of polyphenols.13 Generally speaking, plant polyphenols, as defined above, have 
been implicated in diverse functional roles, including plant resistance against microbial pathogens and 
animal herbivores such as insects (antibiotic and antifeeding actions), protection against solar radiation 
(screens against DNA-damaging UV-B light), which probably was a determining factor in early 
terrestrial plant evolution, as well as reproduction, nutrition, and growth, notably through interactions 
with other organisms above and below ground (insects, symbiotic fungi, and bacteria).13 Over the 
course of long-term evolution, as well as compulsory quick seasonal adjustments, plants have learnt to 
cope with changing environmental conditions and pressures by relying on the formidable chemical 
arsenal available to them through their remarkably dynamic secondary metabolisms, endless sources of 
structural diversity, and variation.13 Of course, among the main groups of secondary metabolites, others 
such as alkaloids and terpenoids have also demonstrated their value in protecting plants during their 
evolution, while contributing by chemical means to maintain a fair ecological balance between plants 
and other living organisms, many of which feeding on them, including humans. However, plant 
phenolics arguably deserve a special mention if we consider the wide-ranging benefits that they offer to 
plants and hence to other living organisms are essentially all a result of their inherent physicochemical 
properties bundled within the phenol functional group (Scheme 1.1). 
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Scheme 1.1 Basic physicochemical properties and reactivities of the phenol functional group. E = Electrophile, Nu = 
Nucleophile. 
A tremendous increase in the number of scientific publications on “polyphenols” has appeared over the 
course of the last 20 years. Such reports include numerous epidemiological studies that have confirmed 
the potential value of these natural products for the prevention of agerelated diseases. These studies 
show that polyphenols act as scavengers of free radicals and reactive oxygen species, which are 
overproduced under oxidative stress conditions and unable to be subdued by the regular action of 
endogenous cellular antioxidants such as glutathione (GSH), glutathione peroxidase, or superoxide 
dismutase, or by dietary antioxidant vitamins (for example, vitamins E and C, carotenoids). 
It did not take long for the cosmetic industry to exploit polyphenols extracted from various plant parts, 
including diverse fruits, herbs, nuts, grape seeds, and tree barks, in their development of new lines of 
products that aimed to better protect the skin from damages caused by solar radiation and aging. The 
food industry did not stand still and initiated the development of functional foods or “nutraceutics” 
based on the use of selected natural polyphenolic molecules as additives.14 
The most talked about characteristic of polyphenols, and plant phenolics in general, is without doubt 
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their acclaimed capability to scavenge reactive oxygen species (ROS), which include radical and non-
radical oxygen species such as O2-x, HOx, NOx, H2O2, 1O2, HOCl, as well as oxidatively generated free 
radicals ROx and ROOx such as those derived from biomolecules such as low-density lipoproteins 
(LDLs),15 proteins, and oligonucleic acids (DNA and RNA).16 All these species can have deleterious 
effects on human health.17,18,19 
This so-called antioxidation ability is frequently cited to be the key property underlying the prevention 
and/or reduction of oxidative stress-related chronic diseases and age-related disorders such as 
cardiovascular diseases (for example, atherosclerosis), carcinogenesis, neurodegeneration (for example, 
Alzheimer’s disease), as well as skin deterioration, by dietary plant (poly)phenolics and other plant 
polyphenol-containing commodities. 
In view of the overwhelming emphasis that has been rightly or wrongly placed on plant polyphenols as 
“super” antioxidants, it’s important to describe the fundamental aspects of the chemistry behind it. 
Plant (poly)phenolic compounds can act as antioxidants by chelating metal ions such as 
iron(II)/copper(I) and iron(III)/copper(II) ions that are involved in the conversion of O2-x and H2O2 into 
highly aggressive HOx through Haber-Weiss/Fenton-type reactions.20,21 They can also block the action 
of some enzymes responsible for the generation of O2-x, such as xanthine oxidase and protein kinase 
C.22 However, it is through the direct quenching of radical ROS and/or free radicals in general that 
(poly)phenols appear to best exhibit their protective role. A synergistic antioxidant action through the 
regeneration of other potent antioxidants such as D-tocopherol (D-TOH; D-TOx + ArOH Æ D-TOH + 
ArOx) is another conceivable option that has also been examined.22,23 
Two main antioxidation mechanisms have been proposed.24 The first is based on the aforementioned 
capacity of the phenol functional group to donate a hydrogen atom to a free radical Rx, such as peroxy 
radicals LOOx generated during lipid (LH) autoxidation (peroxidation; LH Æ Lx, then Lx + 3O2 Æ 
LOOx). In this case, the (poly)phenols act as chain-breaking antioxidants. Through this so-called 
hydrogen-atom transfer (HAT) mechanism, the phenolic antioxidant (ArOH) itself becomes a free 
radical (ArOx; Scheme 1.2).  
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Scheme 1.2 Hydrogen-atom transfer and single-electron transfer are the main mechanisms through which plant 
(poly)phenols express their radical-scavenging-based antioxidant action. The dissociation energy (BDE) and the ionization 
potential (IP) of the phenol are the two basic physicochemical parameters that can be used to determine the potential 
efficacy of each process, respectively.  
The efficiency of the antioxidant action essentially relies on the rapidity of the H-atom transfer to LOOx 
(ArOH + LOOx Æ ArOx + LOOH) and on the stability of the resulting phenoxy radical ArOx, which 
should neither react back with LOOH nor react with the substrate LH, hence terminating the 
propagating radical chain reaction (LOOx + LH Æ LOOH + Lx). The ease of formation and stability of 
ArOx is strongly dependent upon the structural features of the ArOH parent compound. The most 
important determining factors are the presence, number, and relative position of additional phenolic 
hydroxy groups, their implication in the formation of intramolecular hydrogen bonds,25 and the 
conformationally dependent possibility of allowing electronic delocalization throughout the largest part 
of the molecule. All of these factors affect the dissociation energy of the phenolic O-H bond: the 
weaker the O-H bond, the easier the H-atom transfer will be. 
The second mechanism is the single-electron transfer (SET) from ArOH to a free radical Rx with 
formation of a stable radical cation ArOHx+ (Scheme 1.2). The ionization potential (IP) of ArOH is thus 
another important physico-chemical parameter for assessing the antioxidant efficacy of plant 
(poly)phenols: the lower the ionization potential, the easier the one- electron transfer is.  
Numerous techniques have been developed to evaluate the antioxidant capacity of plant (poly)phenols, 
essentially all based on monitoring directly or indirectly the decay of radical species and on 
determining the rate constants for radical scavenging.15,22,26,27 For example, Jovanovic et al., then Bors 
and Michel, relied on pulse radiolysis to evaluate the reactivity of various polyphenols with HOx, O2-x, 
and N3x.28,29 Bors and Michel suggested that flavanols such as (epi)catechin, epigallocatechin, 
epicatechin gallate, epigallocatechin gallate (EGCG), and oligomers thereof (proanthocyanidins) are 
better radical scavengers than many monomeric flavones and even flavonols. The reason for this is 
their (multiple) expression of catecholic and pyrogallolic moieties as privileged radical-scavenging 
sites. The increasing rates of reactions with the highly reactive HOx species (t1/2 ≈10-9 s) nicely 
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correlated with the number of phenolic units bearing adjacent hydroxy groups.28 Extensive structure–
activity relationship studies have been carried out on large numbers of plant polyphenols by relying on 
numerous antioxidation activity assays, notably based on the ability of an antioxidant to scavenge the 
2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) radical cation (ABTS+x) in comparison to that of 
the water-soluble vitamin E analogue Trolox (6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic 
acid) or to scavenge the 1,1-diphenyl-2-picrylhydrazyl radical (DPPHx). Determining the ability of an 
antioxidant to inhibit copper(II) -or 2,2’-azobis(2-amidino-propane) dihydrochloride (AAPH)-induced 
LDL peroxidation is another option. All of the assays unveiled more or less the same trends.15,21,26 
1.4 Polyphenol-protein interactions: pharmacological properties of natural polyphenols 
 
For a long time, the biological activities of plant polyphenols in plant, as well as in humans, have 
arguably been attributed to their capacity to exert antioxidant actions (as discussed above) and/or to 
their propensity to form precipitating complexes with proteins in a rather nonspecific manner.31,32 
Today, there is compelling evidence that strongly suggests that the mechanisms by which plant 
polyphenols exert their protective actions against cardiovascular and neurodegenerative diseases, as 
well as cancer and diabetes, are not simply due to their redox properties, but rather to their ability to 
directly bind to target proteins (or peptides). Such a mode of action would induce the inhibition of key 
enzymes, the modulation of cell receptors or transcription factors, as well as the perturbation of protein 
(or peptide) aggregates, which can regulate cell functions related to, for example, growth and 
proliferation, inflammation, apoptosis, angiogenesis, metastasis, and immune responses, in various 
ways by affecting signal transduction pathways.33,34,35,36 Numerous reports describe the significant 
inhibition of various enzymes by various polyphenols.33,34,37,38, Among the most therapeutically 
relevant enzymes are inflammatory ones such as COXs and LOXs, CYPs, signal transduction kinases 
(generally inhibited more strongly by simple flavonoids, ellagitannins, and ellagic acid than by 
gallotannins and condensed tannins39), xanthine oxidase, NADH-oxidase, thioredoxin reductase,40 
adenosine deaminase, matrix metalloproteinases,41 telomerase, DNA polymerases,42 topoisomerases 
and methyl transferases, ATPase/ATP synthase,43 ornithine decarboxylase, as well as urokinase, an 
enzyme required by human tumors to form metastases and notably inhibited by EGCG.44 
The current appreciation of the capacity of several plant polyphenols to modulate cellular signaling 
cascades by binding to specific target proteins has certainly refreshed opinions on polyphenol-protein 
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interactions, and should provide a new impetus for (re)considering polyphenolic compounds in 
pharmacological drug developments. It is important to emphasize, again, that the structural diversity of 
plant polyphenols is huge, and that the manner with which they can interact (specifically or not) with 
proteins strongly (and mutually) depends on both their physicochemical characteristics and those of 
their protein partners.  
 In the previous years, the ability of polyphenols to strongly associate with proteins with a high proline 
content was clearly established45 and the molecular interactions of polyphenols with proline-rich 
proteins (PRPs) in saliva were examined in detail, notably in relation to the phenomenon of astringency. 
NMR spectroscopic analyses of complexes formed between different polyphenols and model peptides 
mimicking extended polyproline helices of PRPs were performed, and some details of the association 
between the 1,2,3,4,6-penta-O-galloyl-E-D-glucopyranose (E-PGG) and the mouse salivary proline-rich 
peptides were then revealed.46 A preference for an interaction between the pyrolidine ring of prolyl 
groups and the aromatic ring of galloyl units (s-p attraction) was thus discerned, in tandem with the 
deployment of hydrogen bonds between the carbonyl group of the peptide residue preceding the proline 
unit and one of the meta-hydroxy groups of the E-PGG moieties (Figure 1.8).47,48 
  
Figure 1.8 Proposed interaction between the 1,2,3,4,6-penta-O-galloyl-E-D-glucopyranose (β-PGG) and a prolyne residue 
with formation of a hydrogen bond with its preceding amide bond; G = galloyl (3,4,5-trihydroxybenzoyl).
47,48
  
This selectivity for proline residues was, however, challenged in the case of the complex formed 
between Gly-Pro-Gly-Gly and the procyanidin B3 catechin-(4DÆ8)-catechin, for which no preferential 
interaction with the proline residue was observed.49 
Numerous other studies, using either peptides or full-length proteins and various polyphenolic 
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molecules, have been carried out over the years to provide further insight into the physicochemical 
basics that govern polyphenol–protein complexation (and precipitation). The aim of these studies was 
not just understanding the astringent effect of dietary polyphenols, but also how their binding to 
proteins could affect (not necessarily negatively) their biological activities, including their antioxidant 
action, and their bioavailability.37,50 
In the case of PRPs, hydrophobic stacking of phenolic rings against proline rings would constitute the 
primary associative driving force, followed by the formation of hydrogen bonds between phenolic 
hydroxy groups and carbonyl groups linked to proline amino groups, hence stitching up the resulting 
complex (Figure 1.8).32 However, some researchers have suggested that the principal driving forces 
towards association are instead governed by hydrogen bonding between the carbonyl groups of proline 
residues and the phenolic hydroxy groups.45,51,52 It is from these observations that Haslam proposed that 
the less hydrophilic the polyphenol, the better is its ability to complex with proteins,53 at least with 
extended random-coil type proteins such as salivary PRPs, collagen (or gelatin), casein, as well as 
peptides such as bradykinin, or loosely structured globular proteins such as BSA. Kawamoto et al. 
proposed a follow-up two-stage process for the precipitation of BSA by galloylated glucose derivatives 
(Scheme 1.3).54 
 
 
Scheme 1.3 Two-stage process for the precipitating complexation of BSA by gallotannin-like “hydrophobic” 
galloylglucopyranoses. For complexation, more than 3 galloyl units are required per galloylglucose, for precipitation, a total 
of more than 30 galloyl units per BSA is required.  
The first stage in this process is a complexation between the protein and those polyphenols bearing a 
minimum number of three available-for-binding galloyl groups, until a “hydrophobic” coat is formed 
around the protein. Precipitation would commence during the second stage, once the total number of 
galloyl units bound to BSA reaches 30 units. It certainly does not entirely apply to all types of 
polyphenols and proteins, and probably also depends on the experimental conditions used that may or 
may not be relevant to the conditions encountered in natural systems. One example is the relative 
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concentrations of the protein and the polyphenol involved.55,56 In this regard, most of the literature data 
converge to elect water-soluble higher proanthocyanidin oligomers -especially those harboring 
regularly (4DÆ8) linked sequence- as being the best precipitators of PRPs. The multiple phenolic 
moieties (catechol and/or pyrogallol Brings) made available for binding by virtue of their helical 
threadlike shape57 would be particularly well suited to interact in a cooperative manner with multiple 
sites on conformationally extended proteins,58,59,60,61 notably at pH values near their isoelectric points.45 
In contrast, tightly coiled globular proteins have much lower affinities for proanthocyanidins. Recent 
studies have clearly established that not only resveratrol but also the tea 3-O-galloylated flavanol 
EGCG exerts antifibrillogenic properties, which are of value for the fight against human protein 
misfolding disorders involved in neurodegenerative pathologies. For example, Wanker and co-workers 
showed that EGCG binds directly to natively unfolded amyloid-E (AE) and D-synuclein (DS) 
polypeptides, and hence prevents their aggregation into toxic E-sheet-rich fibrillar AE and DS 
oligomers that are implicated in the development of Alzeihmer’s and Parkin- son’s diseases, 
respectively.62 These authors proposed interesting mechanisms of the inhibitory action of EGCG 
against E-sheet formation (and aggregation) of DS. By preferentially binding to a highly flexible region 
of this peptide, EGCG would promote the rapid self-assembly of EGCG-bearing monomers into highly 
stable unstructured DS oligomers, thus redirecting E-sheet-forming and aggregation-prone molecules 
toward a different and nontoxic assembly pathway (Figure 1.9 A). Furthermore, EGCG-stabilized 
monomers and lower oligomers would not be incorporated into preformed amyloidogenic E-sheet 
intermediates, hence interfering with the seeded aggregation pathway to amyloidogenesis, and might 
thus even be able to antagonize the fibrillogenic process even after fibrils had started to accumulate 
(Figure 1.9 B).62  
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Figure 1.9 Models to explain the effects of EGCG on aS fibrillogenesis: A) Amyloidogenesis of monomeric polypeptides, 
which exist in equilib- rium between unfolded and partially folded conformations, proceeds via oligomeric states to amyloid 
fibrils. EGCG preferentially binds to unfolded polypeptide chains and prevents amyloidogenesis by induc- ing the formation 
of unstructured, seeding-incompetent, and nontoxic oligomers. B) EGCG prevents monomer and lower oligomer addition to 
amyloid b-sheet intermediates, thus interfering with the seeded aggregation pathway to amyloidogenesis. 
 
All of these investigations on the interactions between polyphenols and amyloidogenic or prionogenic 
polypeptides show great promise for the design of polyphenol-inspired fibrillogenesis inhibitors as 
therapeutic agents for the treatment of neurodegenerative diseases.63 
However, all of the structure types mentioned, including monomeric flava/flavonoids and 
hydroxystilbenes such as resveratrol and even its glucoside piceid, are “true” polyphenols according to 
the proposed definition. All of the lignan/neolignan dimers displaying two free phenolic moieties and 
lignin polymers also fit this definition. Among other plant-derived phenolic compounds that have been 
the subject of intensive investigations on account of their remarkable biological activities, the 
ellagitannin metabolite ellagic acid, which is naturally present in many red fruits and berries, the 
phenylpropanoid-derived pigment curcumin, isolated from Curcuma spp. such as turmeric (Curcuma 
longa), and the flavonolignan silibinin,64 isolated from Silybum marianum seeds, are also “true” 
polyphenols (Figure 1.10). 
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Figure 1.10 Plant polyphenolic: to be or not to be!  
1.5 Silibinin: a flavonolignan extracted from the milk thistle 
 
Silibinin is a flavonolignan extracted from milk thistle (Silibum marianum L.). As the flavonolignan 
name suggests, this class is derived from the oxidative condensation, through a radical reaction, 
between a flavonoid and a lignan (phenyl-propanoid). In the specific case, the flavonolignan extracted 
from milk thistle are derived from the non-stereoselective reaction between the taxifolin (flavonoid) 
and coniferyl alcohol (lignan).  
One-electron oxidation of taxifolin generates a free radical, a highly unstable species with a strong 
reactivity, which combines with the free radical generated by the coniferyl alcohol. It has, therefore, the 
formation of a specific product, which can be structured in different ways, generating a mixture of 
metabolites known as Silymarin (Scheme 1.4). The latter consists of several flavonolignan present, in 
their turn, in the form of diastereomeric mixtures. 
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 Scheme 1.4 Reaction between taxifolin and coniferyl alcohol to form the silibinin precursor. 
The milk thistle is a biennial spontaneous plant of the Asteraceae family (Figure 1.11), very abundant 
in the entire Mediterranean basin, in southern Russia, North Africa and the eastern part of the United 
States of America. Its fruits are harvested in late summer to be subjected to beating and drying; what is 
obtained from the extract is a complex of flavonolignan named by Wagner "Silymarin", in which the 
main component (about 50-70% of the entire complex) appears to be the silibinin (Figure 1.11), 
mixture of two diastereoisomers, silybin A and silybin B, present in a ratio of 45:55 respectively.65 
   
Figure 1.11 Silybum marianum (Carduus marianus L., Asteraceae; milk thistle); structure of silibinin and its 
diastereoisomers: silybin A and silybin B. 
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Over the years different modes of numbering for silibinin have been proposed.66 In this thesis we used 
a systematic numbering as shown in Figure 1.11. 
 
 
1.5.1 Biological activities of silibinin 
Over the last two decades silymarin, and so it’s most abundant component silibinin, returned to the 
attention of the scientific community for reasons not directly related to its antioxidant capacity, but for 
it’s numerous biological activities (Figure 1.12).  
 
 
Figure 1.12 Biological properties recognized to the silymarin. 
For example, a great number of studies conducted on silibinin to assess the anti-cancer activity, have 
shown that it is capable of: 
• stop the cell cycle in G1 with a cyclin-dependent mechanism;67  
• reduce tumor growth following the downregulation of EGFR;68 
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• reduce the expression of HER2 in breast cancer; 
• induce apoptosis in p53 wild-type cells;69 
• inhibit the activation of ERK1/2 and Akt, overexpressed in aberrant phenotypes of some solid tumors; 
• inhibit angiogenesis by preventing the expression of VEGF, iNOS, COX-2 and NOS3;69 
• modulate the activity of P-glycoprotein by binding competitively to the intracellular domain that 
binds ATP and inhibits the extrusion of cytotoxic chemotherapy drugs;70 
• inhibit the expression of telomerase.71 
In view of these activities, silibinin can fill the role of adjuvant antineoplastic terapy.  
Also, some researchers have investigated the anti-inflammatory activity of the silibinin, due to its 
ability to inhibit the nuclear translocation of the nuclear factor kappa-light-chain-enhancer of acvated B 
cells (NF-kB), preventing the cascade of transduction that is under the control of this important 
transcription factor (Figure 1.13).72 
 
Figure 1.13 Mechanism of NF-kB activation.  
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NF-kB is sequestered in the cytosol by its inhibitor IκB-α which is degraded when phosphorylated by 
IκK, and the transcription factor can move into nu-cleo increasing the transcription of mRNA encoding 
cytokines (IL-1β, IL- 6, IL-11, TNF-α), chemokines (IL-8, CCL5), proinflammatory enzymes (iNOS, 
COX-2, LA-2, 5-LOX), adhesion molecules (CD-54, CD106, CD62E), receptors (CD25, β chain of the 
TCR) and proteins involved in apoptosis (bcl-2, IAPs, cCD95).  
The neuroprotective action of silibinin, instead, is explicated through antioxidant activity and 
inhibition of NF-kB: it is known that oxidative stress is one of the major causes of diseases such as 
Alzheimer or multiple sclerosis. The silibinin was tested as in vitro neuroprotectant, proving to increase 
the cell survival in cultures dispossesed of NGF (nerve growth factor).73 
Some researcher proved that silibinin has, also, antiviral properties. Hepatitis C is an infectious 
disease caused by the hepatitis C virus (HCV, Hepatitis C Virus). In most cases the infection is 
asymptomatic, but in severe cases it may progress to cirrhosis, fibrosis and hepatic cancer. It is known 
that fibrosis is accompanied by loss of tissue function and is manifested as a result of damage to 
stromal or parenchymal cells, which are then replaced by connective tissue. In this context it can placed 
the most important and recognized biological activity of silibinin and, more general of silymarin, 
against chronic liver diseases, cirrhosis and hepatocellular carcinoma, because of antioxidant, anti-
inflammatory and antifibrotic power. Indeed, the anti-oxidant and anti-inflammatory effect of silymarin 
is oriented towards the reduction of virus-related liver damages through inflammatory cascade 
softening and immune system modulation. It also has a direct antiviral effect associated with its 
intravenous administration in hepatitis C virus infection. With respect to alcohol  abuse, silymarin is 
able to increase cellular vitality and to reduce both lipid peroxidation and cellular necrosis. 
Furthermore, silymarin/silybin use has important biological effects in non-alcoholic fatty liver disease. 
These substances antagonize the progression of non-alcoholic fatty liver disease, by intervening in 
various therapeutic targets: oxidative stress, insulin resistance, liver fat accumulation and mitochondrial 
dysfunction. Silymarin is also used in liver cirrhosis and hepatocellular carcinoma that represent 
common end stages of different hepatopathies by modulating different molecular patterns.74 In vivo 
studies have demonstrated that silibinin is capable of reducing the deposition of collagen, lipid 
peroxidation and the proliferation of hepatic cells in rats with induced fibrosis,75 thanks to the 
inhibition of NF-kB factor. The latter controls the synthesis of factors involved in inflammatory states 
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such as IL-1, which, in turn, induces the synthesis of MCP-1, protein responsible for the chemo-
attraction of monocytes 1 and tissue remodeling of fibrotic phenotype. 
It also has been shown that silibinin acts on the glucose metabolism as it is capable of modulating the 
up-take of glucose in adipocytes, blocking GLUT 4 (between the conveyor-insulin-dependent 
glucose).76 In addition, studies in rat hepatocytes have shown that it, in a concentration range between 
25 and 100 mmol/L, can reduce gluconeogenesis and glycogenolysis, block the hydrolysis of glucose-
6-phosphate, inhibit pyruvate kinase and glucose-6-phosphatase. 
From the many biological data available, it is possible to observe that the silibinin may be used in the 
field of pharmacology for treatment of numerous diseases. Pharmacokinetic studies have shown that 
the silibinin, taken orally (in the form of silymarin), is not toxic, even at high doses. However, in vivo 
studies have shown that its bioavailability is very poor not only because it is susceptible to metabolism 
in liver enzymes of phase II, but also because its low solubility in water limits the absorption (which 
takes place at the stomach level). 
Both the free form of the silibinin and its conjugates show a rapid distribution tissue that occurs thanks 
to the presence of endogenous lipoproteins, which act as carriers for transport to the extra-hepatic 
compartments. The bile concentration of silibinin is two orders of magnitude higher than plasma: in 
fact, its elimination is mainly through the biliary excretion (although a discrete portion enters the 
enterohepatic recirculation), while a small percentage (about 5% of the total dose) is excreted in the 
urine.77 
1.6 Synthesis of silibinin modified: state of art 
The growing number of experimental data for pharmacological studies to understand silibinin action 
mechanisms have directed research towards the synthesis of new analogues, molecules with greater 
solubility and bioavailability. In this context, however, the synthetic efforts to date are still limited and 
the number of new analogues synthesized and subjected to biological assays is very small. The first and, 
currently, only drug that present silibinin as active ingredient came into therapy is Legalon® SIL, 
produced by Rottapharm Madaus, and used in the treatment of hepatic acute intoxication by 
mycotoxins.78 Its active ingredient is the sodium salt of silibinin bis-succinate (Figure 1.14) that has a 
greater solubility in water; in fact, the preparation can be administered intravenously but presents 
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considerable limitations, because it is an extremely expensive drug that requires patient hospitalization. 
Over the years the poiesis of analogues has not stopped and between all the available examples (ethers, 
esters, glycoside, product of oxidation and isomerization),79 worthy of note emerges the silibinin 
phosphate (Figure 1.14), synthesized for the first time in 1997 that appears to be a pro-drug activated 
by endogenous phosphatase, and exhibits greater solubility in water.80 
 
 
Figure 1.14 Structures of silibinin bis-succinate and silibinin phosphate. 
Moreover, another drug based on silibinin is commercially available. It comes to a lipophilic 
preparations not obtained by chemically modifying the molecule, but creating a non-covalent complexe 
with phosphatidyl choline (Silipide, IdB 1016, Indena, IT).81,82 This complex possess not only better 
bioavailability than silibinin but also exhibited higher antioxidant activities.83,84 Silipide, also, exhibits 
promising anticancer activities as was demonstrated by its significant inhibition of the growth of human 
ovarian cancer xenografts.85 
Some researchers, over the years, have focused their work on the development of new analogues based 
on silibinin. For example, Křen and his collaborators have developed two selective acylation methods 
for silibinin esterification with long-chain fatty acids were, yielding a series of silibinin 7-O- and 9’’-O-
acyl-derivatives of varying acyl chain lengths (Figure 1.15). These compounds were tested for their 
antioxidant (inhibition of lipid peroxidation and DPPH-scavenging) and anti-influenza virus activities. 
The acyl chain length is an important prerequisite for both biological activities, as they improved with 
increasing length of the acyl moiety. 
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Figure 1.15 Silibinin 7-O- and 9’’-O-acyl-derivatives. 
At the same way, in the research group of Křen have been prepared silibinin dimers and glycosides. 
Silibinin glycosides (9’’-O-β-glucoside, β-galactoside, β-lactoside and β-maltoside, Figure 1.16) have 
been synthesized by different methods (Helferich glycosylation, Lewis acid catalysis) and their 
cytoprotective effects of were studied in isolated rat hepatocytes intoxicated by CCl4 (10 mM).86 
Reduction in the lactate dehydrogenase (LDH) leakage was higer for the new synthesized compounds 
than the silibinin. Similar results were obtained in hepatocytes intoxicated with tert-butyl 
hydroperoxide and allyl alcohol.87  
 
Figure 1.16. Silibinin glycosides. 
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The same researchers have proposed, also, the chemical synthesis of silibinin dimers (Figure 1.17), in 
which the monomer units are linked to each other by an ether spacer. Various biological in vitro tests 
have been used to investigate the behavior of the products, and, as expected, DPPH-scavenging and 
inhibition of microsomal lipid peroxidation was slightly improved by dimerization.  
 
Figure 1.17 Silibinin dimers. 
Our research team, in recent years, is engaged in the synthesis of new silibinin analogues with chemical 
changes for the improvement of the water solubility of this metabolite, without affecting the properties 
of radical scavenger.88 For this purpose has been developed a synthetic strategy for obtaining analogues 
modified in position 9" of the silibinin and the 2,3-dehydro-silibinin, with functional groups able to 
confer to the molecule a greater solubility. From a structural analysis of silibinin, we can see that five 
hydroxyl groups of different nature are present; in fact, the groups present in positions 5, 7 and 4' are 
phenolic type, while in position 3 and in position 9" there are a primary and a secondary hydroxyl 
group, respectively. The choice of insert conjugates on position 9" it has also been dictated by the fact 
that changes in this position did not seem to alter the antioxidant capacity of silibinin.89 
 
The different hydroxyl groups of the silibinin were protected with orthogonal functional groups. This 
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strategy has enabled the obtaining of a key intermediate useful for insertion of various chemical 
changes in position 9". For this purpose, new analogs were obtained by introducing in position 9" a 
sulphate function, a phosphodiester function and an amino function (Figure 1.18). Similarly new 
analogues were obtained for the 2,3-dehydro-silibinin. 
 
Figure 1.18 Silibinin analogs obtained by introducing in position 9" a sulphate function, a phosphodiester function and an 
amino function. 
The antioxidant capacity of the analogues obtained was evaluated in vitro with the DCFH-DA (2', 7'-
dichlorofluorescein diacetate), using rat fibroblasts, allowing to measure the levels of ROS converted 
into more stable species. The results showed that all analogues have reduced levels of ROS present in 
basal conditions and were able to prevent the formation of H2O2 more efficiently than the silibinin. The 
analysis of the data led to the conclusion that the modifications made to increase the hydrophilicity of 
silibinin, and do not change, as expected, the antioxidant capacity but, instead, in most cases the 
antioxidant activity was greater than the silibinin. Were also performed cytotoxicity assays using a 
viability test conducted with MMT in which the rat fibroblasts were pre-incubated with increasing 
concentrations of analogues (0-800 μM) and their viability was assessed spectrophotometrically after 
48 hours. A reduction in cell viability was observed in all compounds with IC50 range of between 124 
and 178 μM (the silibinin showed IC50 of 162 μM) and no toxic effects were observed for 30 μM 
values (used to evaluate the activity antioxidant). 
Moreover, as a part of the continuing research effort towards the synthesis of new natural product 
analogues of my research group90,91 an efficient synthetic procedure to obtain 9’’-phosphodiester 
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silibinin conjugates with different labels, aiming to improve the bioavailability, the delivery as well as 
the biological activity, was carried out. Particularly, some molecules known for their ability as 
molecular carriers (steroids, bile acids),92,93 radical scavengers (nucleosides),94,95 and capable to 
improve water solubility (as polyether)96,97 have been selected (Figure 1.19). The introduction of a 
phosphate group may bring pharmaceutical and pharmacokinetic benefits90 and conjugation is usually 
considered as an efficient route in drug discovery to improve the biological properties of a large 
number of drugs and can improve the bioavailability and delivery as well as the biological activity. 
Also in this case the different hydroxyl groups of the silibinin were protected with orthogonal 
functional groups, leading to obtain the 9’’-phosphoramidite building block 3 (Figure 19) and, starting 
from it, a series of conjugates were used to obtain new analogues by a solution-phase parallel array 
protocol, exploiting standard and reliable phosphoramidite chemistry.90 
 
Figure 1.19 Synthetic procedure to obtain 9’’ phosphodiester silybin conjugates with different labels. 
 
As described up to now demonstrates that the application of synthetic strategies to improve the 
pharmacological and pharmacodynamic characteristics of the molecule leads to obtain biologically 
active molecules. Therefore, the future challenge lies in the application of new synthetic strategies to 
increase the number of new analogues. This is, in particular, the objective presented in this PhD thesis, 
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which also aims to identify new molecules that exhibit improved anti-radical and biological activity, 
and therefore possible candidates for the identification of new drugs. 
  
 32 
References 
 
[1] K.B.G. Torsell, Natural Product Chemistry. A mechanistic, biosynthetic and ecological approach. Apotekarsocieteten 
Swedish Pharmaceutical Press, 1997. 
[2] C. Van DrielMurray in Ancient Egyptian Materials and Technology (Eds. P.T. Nicholson, I. Shaw), Cambridge 
University Press, Cambridge, 2000, pp. 299.  
[3] T. White in The Chemistry of Vegetable Tannins A Symposium, Society of Leather Trades Chemists, Croydon, 1956, 
pp. 7–29. 
[4] E. Haslam, Practical Polyphenolics From Structure to Molecular Recognition and Physiological Action, Cambridge 
University Press, Cambridge, 1998. 
[5] J. Bruneton in Pharmacognosie  Phytochimie Plantes Medicinales, 3rd ed. (Ed.: J. Bruneton), Editions Tec & Doc, Paris, 
1999, pp. 369–404. 
[6] L.A. de la Rosa, E. AlvarezParrilla, G.A. GonzàlezAguilar, Fruit and vegetable phytochemicals: chemistry, nutritional 
value, and stability. 1th Edition, J. Wiley & Sons, Inc., 2010. 
[7] IUPAC. Compendium of Chemical Terminolgy, 2nd ed. (Compiled by A. D. McNaught, A. Wilkinson), Blackwell 
Science Oxford, 1997, p. 299.  
[8] J.B. Harborne in Methods in Plant Biochemistry Vol. 1 (Ed.: J. B. Harborne), Academic Press, London, 1989, pp. 1–28.  
[9] D. Ferreira, D. Slade, J.P.J. Marais in Flavanoids  Chemistry, Biochemistry and Applications (Eds. M. Andersen, K. R. 
Markham), CRC/Taylor & Francis, Boca Raton, FL, 2006, pp. 553.  
[10] E. Haslam, Y. Cai, Nat. Prod. Rep. 1994, 11, 41. 
[11] T. Okuda, T. Yoshida, T. Hatano, H. Ito in Chemistry and Biology of Ellagitannins An Underestimated Class of 
Bioactive Plant Polyphenols (Ed.: S. Quideau), World Scientific, Singapore, 2009, pp.1.  
[12] B. Sailler, K.W. Glombitza, Phytochemistry 1999, 50, 869. 
[13] V. Lattanzio, A. Cardinali, C. Ruta, I.M. Fortunato, V.M.T. Lattanzio, V. Linsalata, N. Cicco, Environ. Exp. Bot. 2009, 
65, 54. 
[14] M.G. Sajilata, P.R. Bajaj, R.S. Singhal, Compr. Rev. Food Sci. Food Saf. 2008, 7, 229. 
[15] A. Neudörffer, J.P. Desvergne, D. BonnefontRousselot, A. Legrand, M.B. Fleury, M. Largeron, J. Agric. Food Chem. 
2006, 54, 1898. 
[16] A.S.H. Li, B. Bandy, S.S. Tsang, A.J. Davison, Free Radical Res. 2000, 33, 551. 
[17] J.B. Harborne, C.A. Williams, Phytochemistry 2000, 55, 48. 
[18] D.S. Leake in Phytochemistry of Fruits and Vegetables (Eds.: F. A. TomasBarberan, R. J. Robins), Clarendon Press, 
Oxford, 1997, pp. 287.  
[19] L.R. Ferguson, Mutat. Res. 2001, 475, 89. 
[20] M. Andjelkovic, J. Van Camp, B. De Meulenaer, G. Depae melaere, C. Socaciu, M. Verloo, R. Verhe, Food Chem. 
2006, 98, 23, and references therein. 
[21] N. Sugihara, M. Ohnishi, M. Imamura, K. Furuno, J. Health Sci. 2001, 47, 99. 
 33 
[22] P.G. Pietta, J. Nat. Prod. 2000, 63, 1035, and references therein. 
[23] J.G. Fang, B. Zhou, J. Agric. Food Chem. 2008, 56, 11458. 
[24] J.S. Wright, E.R. Johnson, G.A. DiLabio, J. Am. Chem. Soc. 2001, 123, 1173.  
[25] M.I. de Heer, H.G. Korth, P. Mulder, J. Org. Chem. 1999, 64, 6969. 
[26] K. Furuno, T. Akasako, N. Sugihara, Chem. Pharm. Bull. 2002, 25, 19. 
[27] D. Huang, B. Ou, R.L. Prior, J. Agric. Food Chem. 2005, 53, 1841. 
[28] W. Bors, C. Michel, Free Radical Biol. Med. 1999, 27, 1413. 
[29] S.V. Jovanovic, Y. Hara, S. Steeken, M.G. Simic, J. Am. Chem. Soc. 1997, 119, 5337. 
[30] T. Yokozawa, C.P. Chen, E. Dong, T. Tanaka, G.-I. Nonaka, I. Nishioka, Biochem. Pharmacol. 1998, 56, 213. 
[31] E. Haslam, T.H. Lilley, Y. Cai, R. Martin, D. Magnolato, Planta Med. 1989, 55, 1. 
[32] J.E. Beart, T.H. Lilley, E. Haslam, Phytochemistry 1985, 24, 33. 
[33] M. Zhu, D. Phillipson, P.M. Greengrass, N.E. Bowery, Y. Cai, Phytochemistry 1997, 44, 441. 
[34] C.S. Yang, X. Wang, G. Lu, S.C. Picinich, Nat. Rev. Cancer 2009, 9, 429. 
[35] S. Sang, Z. Hou, J. D. Lambert, C.S. Yang, Antioxid. Redox Signaling 2005, 7, 1704. 
[36] J. P. E. Spencer, Chem. Soc. Rev. 2009, 38, 1152. 
[37] O. Dangles, C. Dufour in Recent Advances on Polyphenol Research, Vol. 1 (Eds.: F. Daayf, V. Lattanzio), WileyBlack 
well, Oxford, 2008, pp. 67. 
[38] A. Scalbert, C. Manach, C. Morand, C. Rémésy, Crit. Rev. Food Sci. Nutr. 2005, 45, 287. 
[39] G.M. Polya, B.H. Wang, L.Y. Foo, Phytochemistry 1995, 38, 307. 
[40] J. Fang, J. Lu, A. Holmgren, J. Biol. Chem. 2005, 280, 25284. 
[41] J.S.Shim, J.H.Kim, H.Y.Cho,Y.N. , S.H.Kim, H.J. Park, B.S. Shim, S.H. Choi, H.J. Kwon, Chem. Biol. 2003, 10, 695. 
[42] D.J. Maloney, J.Z. Deng, S.R. Starck, Z. Gao, S.M. Hecht, J. Am. Chem. Soc. 2005, 127, 4140. 
[43] J. Zheng, V. D. Ramirez, Br. J. Pharmacol. 2000, 130, 1115. 
[44] J. Jankun, S.H. Selman, R. Swiercz, E. SkrzypczakJankun, Nature 1997, 387, 561.  
[45] A.E. Hagerman, L.G. Butler, J. Biol. Chem. 1981, 256, 4494. 
[46] A.J. Charlton, N.J. Baxter, T.H. Lilley, E. Haslam, C.J. McDonald, M.P. Williamson, FEBS Lett. 1996, 382, 289. 
[47] N.J. Baxter, T.H. Lilley, E. Haslam, M.P. Williamson, Biochemistry 1997, 36, 5566. 
[48] N.J. Murray, M.P. Williamson, T.H. Lilley, E. Haslam, Eur. J. Biochem. 1994, 219, 923.  
[49] T. Hatano, R.W. Hemingway, Chem. Commun. 1996, 2537.  
 34 
[50] C. Dufour, M. Loonis, O. Dangles, Free Radical Biol. Med. 2007, 43, 241. 
[51] C. Simon, K. Barathieu, M. Laguerre, J.M. Schmitter, E. Fouquet, I. Pianet, E.J. Dufourc, Biochemistry 2003, 42, 
10385. 
[52] A.E. Hagerman, M.E. Rice, N.T. Ritchard, J. Agric. Food Chem. 1998, 46, 2590. 
[53] E. Haslam, J. Nat. Prod. 1996, 59, 205 , and references therein. 
[54] H. Kawamoto, F. Nakatsubo, K. Murakami, Phytochemistry 1996, 41, 1427. 
[55] C. Pascal, C. Poncet-Legrand, A. Imberty, C. Gautier, P. Sarni Manchado, V. Cheynier, A. Vernhet, J. Agric. Food 
Chem. 2007, 55, 4895. 
[56] J.P. McManus, K.G. Davis, J.E. Beart, S.H. Gaffney, T.H. Lilley, E. Haslam, J. Chem. Soc. Perkin Trans. 2 1985, 1429. 
[57] E. Haslam, Phytochemistry 1977, 16, 1625.  
[58] W.V. Zucker, Am. Nat. 1983, 121, 335. 
[59] C. Poncet-Legrand, C. Gautier, V. Cheynier, A. Imberty, J. Agric. Food Chem. 2007, 55, 9235. 
[60] A.E. Hagerman, M.E. Rice, N.T. Ritchard, J. Agric. Food Chem. 1998, 46, 2590. 
[61] T. Hofmann, A. Glabasnia, B. Schwarz, K.N. Wisman, K.A. Gangwer, A.E. Hagerman, J. Agric. Food Chem. 2006, 54, 
9503. 
[62] D.E. Ehrnhoefer, J. Bieschke, A. Boeddrich, M. Herbst, L. Masino, R. Lurz, S. Engemann, A. Pastore, E.E. Wanker, 
Nat. Struct. Mol. Biol. 2008, 15, 558. 
[63] Y. Porat, A. Abramowitz, E. Gazit, Chem. Biol. Drug Des. 2006, 67, 27.  
[64] R. Gazák, D. Walterová, V. Křen, Curr. Med. Chem. 2007, 14, 315.  
[65] F. Capasso, Farmacognosia: botanica, chimica e farmacologia delle piante medicinali; Spinger, II edizione 2011 
[66] D. Biedermann, E. Vavříková, L. Cvak, V. Křen, Nat. Prod. Rep. 2014, 31, 1138. 
[67] T.W. Flaig, D.L. Gustafson, L.J. Su, J. A. Zirrolli, F. Crighton, G. S. Harrison, A. Scott Pierson, R. Agarwal, L.M. 
Glodé, New Drugs 2007, 25, 139. 
[68] G. Deep, S.C. Gangar, S. Rajamanickam, K. Raina, M. Gu, C. Agarwal, N.H. Oberlies, R. Agarwal, VEGFVEGFR 
Signaling 2012, 7, e34630. 
[69] M. Provinciali, F. Papalini, F. Orlando, S. Pierpaoli, A. Donnini, P. Morazzoni, Riva, A. Smorlesi, Cancer Res. 2007, 5, 
67.  
[70] P. Dubàk, M. Hajdùch, R. Gaẑàk, A. Svobodovà, J. Psotovà, D. Walterovà, P. Sedmeraand, V. Křen, Bioorg. Med. 
Chem. 2006,14, 3793. 
[71] W.P. Thelen, H. Wuttke, M. Jarry, M. Grzmil, R.H. Ringert, J. Urol. 2004, 171, 1934. 
[72] C. Loguercio, D. Festi, World J. Gastroent. 2011, 17, 2288.  
[73] D. Walterovà, V. Křen, Biomed. Papers 2005, 149, 29.  
 35 
[74] A. Federico, M. Dallio, C. Loguercio, Molecules 2017, 22, 191. 
[75] A. Di Sario, E. Bendia, S. Taffetani, A. Omenetti, C. Candelaresi, M. Marzioni, S. De Minicis, A. Benedetti, Dig. Liv. 
Dis. 2005, 37, 869.  
[76] T. Zhan, M.E. Digel, M. Küch, W. Stremmel, J. Füllekrug, J. Cell. Biochem. 2011, 112, 849.  
[77] J.L.W. Wua, C. Linb, T.H. Tsai, J. Ethnoph. 2009, 121, 185.  
[78] U. Mengs, R.T. Pohl, T. Mitchell, Curr. Pharm. Biotechnol. 2012, 13, 1964. 
[79] D. Biedermann, E. Vavříková, L. Cvak , V. Křen, Nat. Prod. Rep. 2014, 31, 1138. 
[80] G. Pifferi, R. Pace, M. Cont, Il Farmaco 1994, 49, 75. 
[81] M. Conti, S. Malandrino, M.J. Magistretti, Jpn. J. Pharmacol. 1992, 60, 315.  
[82] G. Buzzelli, S. Moscarella, A. Gusti, A. Duchini, C. Marena, M. Lampertico, Int. J. Clin. Pharmacol. Ther. Toxicol. 
1993, 31, 456460.  
[83] P. Morazzoni, M.J. Magistretti, C. Giachetti, G. Zanolo, Eur. J. Drug Metab. Pharmokinet. 1992, 17, 39.  
[84] N. Barzaghi, F. Crema, G. Gatti, G. Pifferi, E. Perucca, Eur. J. Drug Metab. Pharmokinet. 1990, 15, 333.  
[85] D. Gallo, S. Giacomelli, C. Ferlini, G. Raspaglio, P. Apollonio, S. Prisley, A. Riva, P. Morazzoni, E. Bombardelli, G. 
Scambia, Eur. J. Canc. 2003, 39, 2403. 
[86] V. Křen, J. Kubisch, P. Sedmera, P. Halada, V. Prikrylová, A. Jegorov, L. Cvak, R. Gebhardt, J. Ulrichovád, V. 
Simánekd, J. Chem. Soc., Perkin Trans. 1997, 1, 2467. 
[87] V. Křen, R. Gebhardt, Cell. Biol. Toxicol. 1997, 13 (Suppl. 1), 58. 
[88] A. Zarrelli, A. Sgambato, V. Petito, L. De Napoli, L. Previtera, G. Di Fabio, Bioorg&Med. Chem. Lett. 2011, 21, 4389. 
[89] R. Gažák, P. Sedmera, M. Vrbacký, J. Vostálová, Z. Drahota, P. Marhol, D. Walterová, V. Křen, Free Radic. Biol. 
Med. 2009, 46, 745. 
[90] A. Zarrelli, A. Sgambato, V. Petito, L. De Napoli, L. Previtera, G. Di Fabio, Bioorg. Med. Chem. Lett. 2011, 21, 4389.  
[91] L. De Napoli, G. Di Fabio, J. D’Onofrio, D. Montesarchio, Chem. Commun. 2005, 2586; and references cited therein.  
[92] P.W. Swaan, K.M. Hillgren, F.C. Szoka, S. Oie, Bioconjugate Chem. 1997, 8, 520. 
[93] V. Janout, C. Di Giorgio, S.L. Regen, J. Am. Chem. Soc. 2000, 122, 2671. 
[94] A.V. Kachur, Y. Manevich,  J.E. Biaglow, Free Rad. Res. 1997, 26, 399. 
[95] Y. Richter, B. Fischer, J. Bio. Inorg. Chem. 2006, 11, 1063. 
[96] S.S. Banerjee, N. Aher, R. Patil, J. Khandare, J. Drug Del. 2012, 10, 39. 
[97] M.E. Giorgi, R. Agusti, R.M. de Lederkremer, Beil. J. Org. Chem 2014, 10, 1433. 
   
 36 
Chapter 2: Results and discussion 
2.1 Aim of the research work 
 
It is known that natural metabolites have played a crucial role in the identification of many of the drugs 
that are on the market today. The natural products used as such as pharmacological preparations 
represent only 5% of the total, but their semi-synthesis derivatives represent more than 50% of the 
drugs in use.1 In the context of the chemistry of natural substances is focused this PhD thesis, in which 
the attention is mainly aimed on the developement of strategies for the realization of new modified 
metabolites based on silibinin. In particular, in the research group where I worked during my PhD 
period, we focused at first on the synthesis, characterization and evaluation of biological activity of 
new glycosylated silibinin derivatives, through a phosphate bridge. At a later stage, the attention was 
aimed at the development of synthetic methods to obtaining oligoflavonoids based on silibinin, and 
investigates their anti-radical activity. 
2.1.1 Synthesis, characterization, evaluation of antioxidant and biological properties and 
investigation of electrochemical behavior of new silibinin glyco-conjugates 
 
Silibinin is a diastereoisomeric mixture of two flavonolignans, namely silybin A and silybin B in a 
approximately 1:1 ratio. Silibinin is one of the flavonoid antioxidants with multiple biological activities, 
mostly related to its radical-scavenging activity. Recently, this metabolite has received attention due to 
its anticancer and chemopreventive actions,2 as well as hypocholesterolemic, cardioprotective, and 
neuroprotective activities.3 Unfortunately, the pharmacological use in vivo of silibinin is dramatically 
limited for its very low water solubility.4,5 To remedy this problem, various procedures are known in 
literature that improve the solubility and bioavailability, and therefore the pharmacokinetic and 
pharmacological properties of the molecule. An example could be the coniugation with phosphorous or 
PEG groups. The presence of phosphate group increase the water solubility and brings the possibility of 
prodrug approach making possible the improvement of its pharmaceutical, pharmacokinetic and/or 
pharmacodynamic properties. In recent years, many efforts have been made to overcome these 
limitations leading to the production of two water soluble derivatives of silibinin, the FlavobionTM and 
LegalonTM, endowed with high hepatoprotective activities are used in chronic liver diseases caused by 
oxidative stress (such as alcoholic and non-alcoholic fatty liver diseases or drug- and chemically-
induced hepatic toxicity).6  
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Another family of molecules suitable to improve the solubility, and therefore the bioavailability, is sure 
that of carbohydrates. In this contest, it has been reported, for the quercetin, natural product endowed 
with potent antioxidant activitiy, that the therapeutic absorption of its modified quercetin glycoside, is 
more efficient than the quercetin aglycon, ascribing this benefit to the hydrophilic character of 
saccharide moieties that increase the water solubility of the aglycon, and enhance its bioavailability.7,8 
Moreover, carbohydrate-based conjugates allow targeting of a certain class of cell membrane receptors 
that recognize a specific carbohydrate motif and internalize their ligands by endocytosis. The presence 
of hydroxyl groups brings the possibility of prodrug approach making possible the improvement of its 
pharmaceutical, pharmacokinetic and/or pharmacodynamic properties.9 
While remaining within of chemistry of silibinin, we dealt with the low water solubility of silibinin that 
dramatically limits its pharmacological use.5 In this frame, we developed a synthetic strategy to obtain 
new silibinin derivatives linking suitable chemical conjugations, in particular glico-conjugation, able to 
improve its applications in biomedicine and biochemisty.10,11 
2.1.2 Synthesis, spectroscopic properties, solubility and anti-oxidative ability of silibinin dimers 
 
As described before, it is shown from the literature that plant polyphenol exhibit an important and 
remarkable antioxidant activity. This activity is mainly performed through two mechanisms: the first 
regards the capacity of the phenol functional group to donate a hydrogen atom to a free radical, acting 
as chain-breaking antioxidants (HAT mechanism) and the second mechanism is the single-electron 
transfer (SET) from the polyphenol to a free radical with formation of a stable radical cation. The most 
important determining factors in this activity are the presence, number, and relative position of 
additional phenolic hydroxy groups, their implication in the formation of intramolecular hydrogen 
bonds,12
 
and the conformationally dependent possibility of allowing electronic delocalization 
throughout the largest part of the molecule.  
In this context, divalent or multivalent molecules often exhibit enhanced biological and antioxidant 
activity relative to the simple monovalent units.13 It is not only the multivalency effect that modifies 
their biological activity (multi-ligand binding) but also their pharmacokinetic parameters, as shown 
recently in artemisinin dimers used as antimalarial drugs.14 The dimerization of flavonoids, aiming at 
the preparation of more effective P-glycoprotein inhibitors, has been accomplished by the synthesis of 
apigenin homodimers linked with polyethylene glycol spacers.15 This study also demonstrated that the 
length of the spacer is a critical parameter for the binding of dimers to the target protein(s). Křen and 
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his collaborators have prepared dimers of silibinin, wherein the monomers are linked to each other by 
short aliphatic chain, using an enzyme-catalyzed and also chemical approach and they show a DPPH-
scavenging and inhibition of microsomal lipid peroxidation slightly improved by dimerization.  
Due to this information, as a part of our continuing research effort towards the synthesis of new natural 
product analogues by a prodrug approach, we have developed an efficient synthesis of dimers linked-
phosphate silibinin.  
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2.2 New Silibinin glyco-conjugates: synthesis and evaluation of anti-oxidant properties 
 
As previously described, therapeutic efficiency of silibinin is rather limited by its low bioavailability 
that limited its affectivity.6 In this contest, it has been reported, for the quercetin, natural product 
endowed with potent antioxidant activitiy, that the therapeutic absorption of its modified quercetin 
glycoside, is more efficient than the quercetin aglycon, ascribing this benefit to the hydrophilic 
character of saccharide moieties that increase the water solubility of the aglycon, and enhance its 
bioavailability.7,8 Moreover, the presence of hydroxyl groups brings the possibility of prodrug approach 
making possible the improvement of its pharmaceutical, pharmacokinetic and/or pharmacodynamic 
properties.9 
Starting from these considerations, we synthesized and biologically characterized, new 9''-silibinin 
conjugates connecting the mono- and di-saccharide residues to hydroxyl anomeric position through 
phosphodiester bond (Scheme 2.1). In our approach 9''-phosphoramidite 1 has been used as silibinin 
substrate and 1-OH full protected mono- and di-saccharide derivatives (2−5, Scheme 2.1) chosen as 
sugar starting materials. We initially converted full acetylated mono and di-saccharides into 1-OH 
derivatives by a reaction with benzylamine in THF at room temperature.16,17 
Thus compounds 2−5 (Scheme 2.1) were coupled with derivative 1 using 0.45 M tetrazole in 
CH3CN/CH2Cl2 (1:1, v:v). After the treatment with 5.5 M tert-butyl hydroperoxide solution in decane 
and subsequently with Et3N/pyridine (1:1, v:v) at 50 °C and conc. aq. Ammonia/MeOH (1:1, v:v) at 
room temperature, the phosphodiester derivatives 6−9 were obtained in good yields. 
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Scheme 2.1. General structures of new silibinin glycoconjugates (top); synthesis of new 9"-glyco-silibinin analogues 
(bottom). 
The crude materials were then subjected to the purification step, by reverse phase analysis (RP-18 
HPLC), using a variety of columns and elution conditions, but unfortunately the mixture of 
diastereoisomers was too much complicated to be purified. In the end new silibinin analogues (6−9) 
were eluted onto Sep-Pak C18 cartridge and were obtained as a mixture of diastereoisomers, as 
observed 31P NMR analysis. All compounds were then converted into the corresponding sodium salts 
by cation exchange on a DOWEX (Na+ form) resin to have crystalline samples. The NMR analysis has 
proved very complex, in fact 1H and 31P NMR spectra of all compound showed a dramatic complexity, 
due to the presence of a complex mixture of diastereoisomers. This drawback has not allowed a 
complete and detailed NMR characterization of the new derivatives. In this preliminary study we show 
the values of the 31P NMR and ESI-MS mass spectra signals. In order to evaluate their antioxidant 
activity, all silibinin derivatives were subjected to 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical 
scavenging assay18 and the Xanthine Oxidase (XO) inhibition models assay (Table 2.1). 
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Table 2.1. Free Radical Scavenging capacity (DPPH) and Xanthine Oxidase Inhibition 
(X/XO) 
Samples IC50 (PM)a Cell viability (%)b 
 DPPH 
scavenging 
 after induction 
of oxidative stress 
Silibinin-9"-phosphoryl-D-
glucopyranoside (6) 
301.7 ± 15.1 89.2 ± 3.1 42.7 ± 3.2 
Silibinin-9”-phosphoryl-D-
mannopyranoside (7) 
108.0 ± 3.2 89.5 ± 2.3 42.3 ± 4.2 
Silibinin-9"-phosphoryl-D-
galactopyranoside (8) 
233.0 ± 14.0 84.1 ± 2.4 42.8 ± 3.6 
Silibinin-9"-phosphoryl-D-
lactopyranoside (9) 
154.7 ± 6.2 91.8 ± 2.1 48.4 ± 3.8 
Silibinin 392.2 ± 7.8 45.3 ± 2.5 42.4 ± 2.9 
2,3-Dehydrosilybin 27.0 ± 0.8 - - 
Quercetin 0.31 ± 0.01 - - 
a. IC50 values (defined as concentrations that inhibites activity by 50%) were calculated 
using data obtained from at least three independent experiments. 
b. (Mean ± SD from three separate experiments run in duplicate, at 10, 25, 50, 100, and 
200 µM). 
 
 
The DPPH test is a non-enzymatic method currently used to provide basic information on the 
scavenging potential of stable free radicals in vitro. On the other hand XO is considered to be the most 
important biological source of free radicals. Many references reveal cerebral microvascular injury 
resulting from XO production of superoxide free radicals.19 XO inhibition is thereby implicated as 
useful approach in treating cerebrovascular pathological changes or Central Nervous System (CNS) 
diseases.20,21 From the DPPH assay shown in Table 2.1, we observed that introducing any sugar 
moieties in position 9" did not led to a significant reduction of quenching properties. For comparison 
purposes, the antioxidant activities of 2,3-dihydrosilybin and quercetin were evaluated as controls. In 
particular the new silibinin derivatives (6−9) showed DPPH radical scavenging activities similar to that 
of the silibinin, confirming that the introduction in 9'' of the sugar moiety did not influence the radical 
scavenging activity of this metabolite.22,23 In basal conditions, the pre-incubation of MKN28 cells with 
6−9 and silibinin lead to two different results (Table 2.1). In fact, 6−9 analogues don’t affect cell 
viability, while silibinin induced a cell death of about 50%, also at the lower dose used. The evaluation 
of cell viability in MKN28 cultured cells after incubation with 6−9 and silibinin, and the subsequent 
induction of oxidative stress, have shown that these molecules protect from cell death under oxidative 
stress, at least as the silibinin. 
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In conclusion, new silibinin glyco-conjugates were synthesized and their antioxidant properties were 
evaluated. Exploiting our solution phase strategy, a variety of structurally diverse silibinin glyco-
conjugates were successfully realized in a short time and in very good yields. New derivatives were 
subjected to DPPH free radical scavenging assay and the Xanthine Oxidase inhibition models assay in 
preliminary study to evaluate their antioxidant activities. Irrespective of the sugar moiety examined, all 
compounds exhibited a radical scavenging activities slightly higher than to silibinin and XO inhibition 
at least as silibinin. In the other hand the new derivatives showed water solubility well above that of 
silibinin, in fact it was possible to prepare solutions of about 70 mg/mL of analogues in water. These 
two data encouraged our studies aimed to improve this synthetic strategy to realize libraries of optically 
pure glyco-conjugated silibinin. 
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2.3 Synthesis, biological and electrochemical investigation of new silibinin glyco-
phosphodiester conjugates  
In our work, of which the details are explained in the previous paragraph, we have combined two 
important aspects of the design and synthesis of soluble prodrugs: the first is the possibility to create 
phosphate ester useful for phenolic and other metabolites containing poorly water soluble drugs to 
enhance their aqueous solubility. Moreover, phosphate prodrugs display excellent chemical stability 
and rapid bioconversion in vivo to the parent drug by phosphatases present in the intestinal brush 
border or in the liver. On the other hand, the second essential aspect for the prodrug strategy was that 
of using a carbohydrate-based conjugates that may be useful as carrier and a target of a certain class of 
cell membrane receptors, which recognize a specific carbohydrate motif and internalize in the cell their 
ligands by endocytosis. In this frame we reported the synthesis of a new class of phosphodiester 
silibinin glyco-conjugates with a good water solubility as well as an attractive antioxidant properties.24 
Unfortunately, NMR analysis has proved very complex, in fact 1H and 31P NMR spectra of all 
compound showed a dramatic complexity, due to the presence of a complex mixture of 
diastereoisomers. This drawback has not allowed a complete and detailed NMR characterization of the 
new derivatives. This aspect, combined with the fact that the new conjugates are much more soluble in 
water and exhibit interesting biological properties compared to the starting molecule, have mainly 
encouraged us on the improving this synthetic strategy in order to realize libraries of optically pure 
glyco-conjugated silibinin derivatives. Infact, as a part of our continuing research effort towards the 
synthesis of silibinin conjugates, our project aimed at developing an efficient method for the synthesis 
of a new silibinin glyco-conjugates in which the structural elements necessary for the antioxidant 
activity are maintained and the saccharide units are linked by a phosphodiester bridge, which is 
hydrolytically labile in the biological fluid. Results of a recent study on the antiradical activity of 
silibinin have elucidated the functional groups responsible for this activity and suggest that the C-9" 
position could be a site for useful modifications aimed to improve the bioavailability. 
Key point of our strategy was the synthesis of 3,5,7,4"-O-tetra-isobutyryl-silibinin-9"-phosphoramidite, 
useful building block to obtain a wide range of silibinin 9"-conjugates with a many type of labels, 
following a reliable and well known phosphoramidite chemistry. Exploiting a combinatorial solution 
phase strategy, structurally diverse silibinin glyco-conjugates (gluco, manno, galacto, lacto, trehalo, 
and N-acetylgluco) were successfully obtained in very good yields (60-72% as sodium salts) and in 
short time (Scheme 2.2). 
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Scheme 2.2 Synthesis and general structures of new silibinin glycoconjugates. 
New 9''-phosphoramidite (3, Scheme 2.3) have been used as silibinin substrate and primary OH full 
protected mono- and di-saccharide derivatives (8−13, Scheme 2.3) chosen as sugar starting materials. 
Using an a selectively and orthogonal approach we started from silibinin and from selected mono- and 
di-saccharides, to synthesized both 3 and 8−13 building blocks in a good yields. We initially converted 
silibinin 1 into 9-ODMT ether by a reaction with DMT-chloride (DMTCl) in pyridine and after an 
exhaustive aceylation treatment with an excess of isobutyryl anhydride, the successive treatment using 
5% formic acid in CH2Cl2 allowed the removal of the DMT protecting group to led 2 in a 61% yield. 
The choice of isobutyryl group was necessary for obtaining a more stable and easily manipulated 
intermediate. Indeed in the detrytilation step it was observed a partial lability of the acetyl group, used 
in previous works, which did not ensure a good efficiency in the purification procedures. 
The intermediate 2 was reacted with 2-cyanoethyl-N,N-diisopropylamino-chlorophosphoramidite and 
DIEA in anhydrous DCM. After purification the identity of compounds 3, obtained in good yields 
(65%), was confirmed by NMR (1H, 13C and 31P) and HRMS-ESI data.  
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Scheme 2.3 a. DMTCl, pyridine, 50 °C; b. isobutyl anhydride, pyridine; c. 5% formic acid in CH2Cl2; d. DMTCl, 
pyridine; e. acetyl anhydride, pyridine; f. 5% formic acid in CH2Cl2; g. I2/Et3SiH, DMC; h. dry CH3OH, Ag2CO3, 3Å MS; i. 
28% NH4OH acq./CH3OH (1:1, v/v), r.t. 
 
For the synthesis of saccharide units (8−13, Scheme 2.3) were followed different routes according to 
the sugar units chosen. Starting from D-1-OMe-monosaccharides (4−7) we initially converted into 6-
ODMT ether and then fully acylated by treatment with an excess of acetyl anhydride in pyridine. The 
treatment using 5% formic acid in CH2Cl2 allowed the removal of the DMT protecting group to led 
8−11 in a good yields (50−70%). The same procedure was used starting from the commercially 
available D,D-trehalose to synthesized the eptaacetyl-trehalose (12, 60%). Regarding the lactose, we 
started from the precursor octaacetil lactose, converting it into the corresponding glycosyl iodide 
intermediate by reaction with iodine (I2) and triethylsilane (Et3SiH) in CH2Cl2 at reflux, for 40 minutes. 
The intermediate obtained was subjected to glycosidation in situ for reaction with MeOH and silver 
carbonate (Ag2CO3) at room temperature for 6 hours, keeping the reaction mixture in low light 
 46 
conditions. Later, also in this case were protected in a orthogonal way the primary and secondary 
hydroxyls with DMT-Cl and acetic anhydride, respectively. 
Building blocks 8−13 (Scheme 2.4) were coupled with silibinin phosphoramidite 3 using 0.45 M 4,5-
dicyanoimidazole (DCI). The treatment with 5.5 M tert-butyl hydroperoxide solution in decane (1 h, 
r.t.) and the subsequent treatment with conc. aq. ammonia and MeOH (1:1, v:v) at 50 °C, allowing full 
deprotection from isobutyryl and cyanoethyl groups. 
 
 
Scheme 2.4 Coupling reaction between Silibinin phosphoramidite 3 and sugar buinding blocks 8−13, giving conjugates 
14−19. 
The crude materials were then subjected to reverse phase analysis and purification (RP-C18 HPLC) 
leading to the desired phosphodiester derivatives 14−19 (Scheme 2.4). All compounds were then 
converted into the corresponding sodium salts by cation exchange on a DOWEX (Na+ form) resin to 
have crystalline samples. New compounds obtained in good yields (50−60%) were thus fully 
characterized by NMR (1H, 13C, 31P) and MALDI-MS. The spectra of all analogues look like that of a 
single compound and the structures of new silibinin conjugates, were determined by NMR 
spectroscopy and the complete assignment was proved by COSY, HMBC and HSQC NMR 
experiments.  
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Table 2.2 13C NMR of 14−19 in CD3OD at 400 MHz (flavonolignan portion). 
             sample 
carbon 
14 15 16 17 18 19 
2 85.46 85.00 
85.03 
84.97 
85.05 
84.97 
85.04 
84.97 
83.33 
83.26 
83.36 
83.28 
3 74.29 73.96 73.98 73.96 72.25 71.37 
4 198.54 198.51 198.67 198.62 198.70 198.68 198.43 
4a 102.02 103.02 102.98 102.13 102.09 102.14 101.94 
5 165.64 164.70 164.68 165.59 165.59 165.58 165.62 
6 97.80 97.84 97.71 97.74 97.73 97.90 
7 169.51 169.46 169.54 169.10 169.25 169.14 
169.88 
169.82 
8 96.77 96.79 96.67 96.72 96.71 96.90 
8a 164.70 164.68 164.70 164.70 164.70 164.69 
1' 131.68 131.80 131.81 131.75 131.87 131.83 
131.83 
131.79 
2' 117.98 117.85 
117.96 
117.86 
117.95* 
117.87* 
117.98 
117.85 117.97 118.00 
3' 145.34 145.35 145.33 145.33 
145.37 
145.32 
145.37 
145.33 117.90 
4' 145.65 145.61 145.62 145.61 
145.67 
145.62 
145.59 
145.57 
145.68 
145.61 
5' 118.25 118.17 
118.27 
118.19 
118.23* 
118.17* 
118.25 
118.17 
118.37 
118.29 145.33 
6' 122.55 122.37 
122.57 
122.46 
122.59 
122.49 
122.59 
122.43 
122.71 
122.68 
168.30 
118.23 
1" 129.55 129.54 129.50 129.57 129.49 129.57 129.55 
2" 112.64 112.60 
112.59 
112.56 
112.58 
112.49 112.59 112.60 
112.64 
112.60 
3" 149.47 149.47 149.49 149.48 149.45 149.48 
149.50 
149.44 
4" 148.53 148.54 148.51 
148.55 
148.54 
148.53 
148.47 148.54 
148.53 
148.49 
5" 116.65 116.60 
116.66 
116.62 116.63 
116.69 
116.64 
116.70 
116.68 116.68 
6" 122.08 122.05 
122.09 
122.02 
122.00 
121.96 122.06 
122.13 
122.08 122.07 
7" 77.89 77.82 
77.82 
77.78 77.76 77.83 
77.79 
77.75 
77.92 
77.81 
8" 78.72 d (4.3)
§ 
78.63 d (3.7)§ 
78.74 m 
78.67 m 
78.80 m 
78.72 m 
78.74 d (8.0)§ 
78.69 d (7.4)§ 
78.83 d (7.5)§ 
78.79 d (7.1)§ 
78.76 m 
78.64 m 
9" 66.11 m 66.36 d (5.3) 65.81 m 65.81 m 68.79 m 65.75 
66.08 m 
65.80 m 
C-4"-OCH3 
56.87 
56.85 
56.89 
56.87  56.86 
56.88 
57.85 57.65 56.90 
* Overlapped signals; § In parenthesis shows JCP in Hz. 
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Table 2.3 13C NMR of 14−19 in CD3OD at 400 MHz (saccharide portion). 
           sample 
carbon 14 15 16 17 18 19 
1 101.40 102.01 101.73 100.01 105.62 95.47 95.46 
2 73.95 73.80 72.30 72.30 55.59 
75,90 
75.87 
73.53 
73.51 
3 75.13 75.07 72.68 71.47 
72.12 
73.08 
76.47 
76.44 
74.66 
74.57 
4 71.54 68.47 70.68 70.59 
72.14 
72.13 82.01 
72.19 
71.75 
5 72.79 d (7.4)
§ 
72.71 d (6.8)§ 
73.69 d (7.2)§ 
73.60 d (7.1)§ 
71.15 d (6.6)§ 
71.08 d (6.0)§ 
72.86 d (7.9)§ 
72.79 d (7.7)§ 72.69 m  
74.07 m 
73.98 m 
6 65.83 d (5.1)
§ 
65.81 d (3.8)§ 
65.85 m 
65.78 m 
65.63 d (3.4)§ 
65.63 d (3.7)§ 
66.17 d (5.2)§ 
66.10 d (5.1)§ 65.87 m 
66.08 m 
65.80 m 
1' - - - - 105.31 95.39 95.33 
2' - - - - 74.89 74.84 
73.53 
73.51 
3' - - - - 75.80 75.70 74.74 
4' - - - - 70.03 69.99 
72.19 
71.75 
5' - - - - 76.67 74.07 73.98 
6' - - - - 62.29 62.95 
1-OCH3 55.86 55.84 55.59 
56.07 
56.03 
55.85 
55.83 56.92 - 
NHCOCH3 - - - 173.99 - - 
NHCOCH3 - - - 22.91 - - 
§ In parenthesis shows JCP in Hz. 
 
Table 2.4 1H NMR of 14−19 in CD3OD at 400 MHz (saccharide portion). 
             
proton 
sample 
1 2 3 4 5 6 1 2 3 4 5 6 OCH3 
14 
4.55 
d 
(4.5) 
3.36 
m 
3.62 
m 
3.39 
m 
3.59 
m 
4.01 
m - - - - - - 3.34 s 
15 4.60 * 
3.78 
m 
3.67 
m 
3.71 
m 
3.56 
m 
4.11 
m 
4.14 
m 
- - - - - - 3.30 s 
16 
4.67 
d 
(3.7) 
3.76 
m 
3.94 
m 
4.06 
m 
3.89 
m 
4.00 
m - - - - - - 3.33 s 
17 4.55 3.92 m 
3.65 
m 
3.45 
m 
3.60 
m 
4.03 
m - - - - - - 3.37 s 
18 
4.36 
d 
(1.3) 
3.55 
m 
3.78 
m 
3.53 
m 
3.58 
m 
4.10 
* 4.23 
3.27 
m 
3.52 
m 
3.86 
m 
3.43 
m 
3.91 
m 
3.86 
m 
3.53 s 
19 5.06 m 
3.48 
m 
3.82 
m 
3.36 
m 
3.84 
m 
4.11 
m 
4.02 
m 
5.09 3.50 m 
3.77 
m 
3.32 
m 
3.82 
m 
3.72 
m 
3.82 
m 
- 
*Overlapped signals 
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Table 2.5. 1H NMR of 14  19 in CD3OD  400 MHz (flavonolignan portion) 
            
proton 
sample 
2 3 6 8 2' 5’ 6' 2" 5" 6" 7" 8" 9" 4"-
OCH3 
1-
OCH3 
14 
4.99 
d 
(11.2) 
4.57 
d 
(11.2) 
4.54 
d 
(11.2) 
5.93 
d 
(1.9) 
5.91 
d 
(1.9) 
7.12 
d 
(1.8) 
7.11 
d 
(1.9) 
7.02 
d 
(8.2) 
7.01 
d 
(8.2) 
7.06 
m 
7.09 
d 
(1.8) 
6.87 
d 
(8.1) 
6.86 
d 
(8.1) 
6.98 dd 
(1.8;8.1) 
5.01 
d 
(7.5) 
5.00 
d 
(7.5) 
4.35 
m 
4.33 
m 
4.11 
m 
3.85 
m 
3.91 s 3.34 s 
15 
4.98 
d 
(11.5) 
4.56 
d 
(11.4) 
5.94* 
d 
(2.0) 
5.91* 
d 
(2.0) 
7.12 
d 
(1.8) 
7.11 
d 
(1.7) 
7.03 
d 
(7.5) 
7.05 
m 
7.09 
m 
6.85 
d 
(8.2) 
6.97 
dd 
(1.7;8.2) 
5.03 
d 
(7.8) 
5.01 
d 
(7.8) 
4.31 
m 
4.12 
m 
3.85 
m 
3.91 s 3.30 s 
16 
5.03 
d 
(11.5) 
4.57 
d 
(11.5) 
5.95 
d 
(1.8) 
5.93 
d 
(1.8) 
7.12 
s 
7.03 
d 
(8.3) 
7.02 
d 
(8.3) 
7.06 
m 
7.08 
m 
6.86 
d 
(8.1) 
6.97 dd 
(1.8;8.1) 
5.02 
d 
(7.5) 
4.27 
m 
4.10 
m 
3.85 
m 
3.91 s 3.33 s 
17 
4.99 
d 
(11.8) 
4.55 
m 
4.53 
m 
5.95 
d 
(2.0) 
5.93 
d 
(2.0) 
7.12 
d 
(1.8) 
7.11 
d 
(1.7) 
7.02 
d 
(8.3) 
7.00 
d 
(8.3) 
7.04 
m 
7.09 
m 
6.87 
d 
(8.1) 
6.86 
d 
(8.3) 
6.97 dd 
(2.0;8.3) 
5.01 
d 
(7.7) 
5.00 
d 
(7.7) 
4.32 
m 
4.10 
m 
3.85 
m 
3.91 s 
3.90 s 3.37 s 
18 4.99 m 
4.57* 
4.55 
m 
5.95 
d 
(2.1) 
5.93 
d 
(2.1) 
7.12 
s 
7.05 
d 
(8.5) 
7.07 
m 
7.08 
m 
6.88 
d 
(8.2) 
6.87 
d 
(8.2) 
6.98 m 
5.02 
m 
5.01 
m 
4.27 
m 
4.12 
m 
4.00 
m 
3.83 
m 
3.91 s 3.53 s 
19 
5.01 
d 
(11.7) 
4.56 
d 
(11.5) 
5.93 
d 
(2.2) 
5.92 
d 
(2.2) 
7.12 
d 
(1.9) 
7.11 
d 
(1.9) 
7.03 
d 
(8.2) 
7.02 
d 
(8.2) 
7.06 
m 
7.08 
d 
(1.8) 
6.88 
d 
(8.0) 
6.87 
d 
(8.0) 
6.97 dd 
(1.8;8.2) 
5.02 
d 
(8.0) 
5.00 
d 
(8.0) 
4.33 
m 
4.28 
m 
4.13 
m 
4.11 
m 
3.91 s  
*Overlapped signals 
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New derivatives were subjected to 2,2-diphenyl-1-picrylhydrazyl free radical scavenging assay (Table 
2.6) and their activities results to be better than that of silibinin 1, which confirmed that the 
introduction in 9'' of the sugar moiety had little effect on radical scavenging activity. As expected the 
new glycosylated were very soluble in water and they exhibited a DPPH radical scavenging activities 
slightly higher than to silibinin. 
Also, since the presence in blood and extracellular fluid of a great number of hydrolytic enzymes, 
among which phosphatase that can break a phosphodiester bond before the active complex can reach its 
molecular target, the stability of the new synthesized conjugates was evaluated in human serum and 
monitored over time by of HPLC analysis. New silibinins glyco-conjugates (14−19) were incubated at 
37 °C with human serum from human male AB plasma in Tris•HCl buffer (pH = 8.0 containing 10 mM 
MgCl2). Small aliquots of the mixture were taken at defined time intervals, kept at 85 °C for 5 min, 
equilibrated at room temperature, and analyzed by HPLC on an RP column. As shown in Table 2.6 the 
conjugates (14−19) are degraded with a time half-lives of 40 to 68 hours. 
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Table 2.6 Summary table of MALDI analysis, HPLC retention times, IC50 and serum half lives for compound 14−19. 
 MALDI tR (min) DPPH IC50(mM) t1/2 (hours) 
14 
calcd for C32H35O18P = 738.16 
[M-H]- = 737.68; [MNa-H]- = 759.80; 
[MK-H]- = 775.20 14.04 1.23 ± 0.075 40.2 
15 
calcd for C32H35O18P = 738.16 
[M-H]- = 737.22; [MNa-H]- = 759.53 
[MK-H]- = 775.28 14.07 1.00 ± 0.068 47.6 
16 
calcd for C32H35O18P = 738.16 
[M-H]- = 737.49; [MNa-H]- = 759.19 
[MK-H]- = 775.68 14.03 0.89 ± 0.078 42.7 
17 
calcd for C34H38NO18P = 779.18 
[M-H]- = 778.58; [MNa-H]- = 800.37 
[MK-H]- = 816.74 14.01 0.98 ± 0.069 45.6 
18 
calcd for C38H45O23P = 900.21 
[M-H]- = 900.35; [MNa-H]- = 921.43 
[MK-H]- = 937.94 13.45 0.93 ± 0.084 59.0 
19 
calcd for C37H43O23P = 886.19 
[M-H]- = 886.65; [MNa-H]- = 907.34 
[MK-H]- = 923.55 13.32 0.94 ± 0.071 68.1 
Silibinin (1)   1.4 ± 0.06  
Quercetin   0.18 ± 0.01  
 
In order to verify the potential biological properties of these derivatives, a biological assay was utilized 
to evaluate the cytotoxicity of new glyco-conjugates, compared with the silibinin, on human liver 
cancer cell line (Hep G2). In this field, no significant changes in the viability of treated cells were 
observed when they were subjected to the action of glyco-conjugates, also considering the longest 
incubation (72 hours) and the maximum dose taken (30 µM). 
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Figure 2.1 Diagrams of the cytotoxicity results for the silibinin and two of its glyco-conjugates (Sil-p-Glc and Sil-p-Lact). 
 
In order to investigate the role of the different OH groups in the antioxidant activity of new glyco-
conjugates in comparison with silibinin, their acidity and redox capacity have been evaluated. These 
results are obtained in collaboration with the group of Prof. Iuliano and Dr De Tommaso, of the 
Department of Chemical Sciences of University of Naples “Federico II”.  
The determination of the acidity constants was conducted by potentiometric titrations measuring the 
hydrogenionic concentration with a glass electrode. The determination of acid-base silibinin and glyco-
conjugates constants is made by evaluation of ZH functions, that represents the average number of 
protons released per molecule. Bringing ZH as function of pH the experimental data are in agreement 
with the solid line obtained with three equilibria. An example of the experimental curve (ZH, -log[H+]) 
is shown in Figure 2.2. 
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Figure 2.2 ZH (pH) function, for Sil-p-Glc, Sil-p-Gal and Sil-p-Man systems. The solid line is calculated using the constants 
of Table 2.7. 
By processing data, it was possible to define three equilibrium constants, both for silibinin and its 
conjugates. The obtained values for silibinin derivatives are similar to silibinin acidity constants. New 
glycosylated show a redox behavior similar to the silibinin and the acidic constants of the phenolic 
groups, very often implicated in the complexation with metals such as (Cu, Zn, Fe) remain unchanged. 
 
Table 2.7. Protolisys constant of Silibinin and some conjugates in 0.1 M NaClO4. 
Compound Silibinina Sil-p-Glc Sil-p-Man Sil-p-Gal  Sil-p-Lact 
pKa1 7.00 ± 0.1 7.20 r 0.06 7.32 r 0.08 7.28 r 0.08 7.27 r 0.07 
pKa2 10.25 ± 0.1 9.45 r 0.09 9.56 r 0.09 9.39 r 0.09 9.40 r 0.09 
pKa3 11.8 ± 0.1 10.9 r 0.1 11.0 r 0.1 11.0 r 0.1 11.1 r 0.1 
a. Protolisys constant measured in 0.1 M NaClO4/50% CH3OH. 
By analogy with the acid-base behavior of known molecules, the values of the acid constants can be 
assigned according to Figure 2.3.  
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Figure 2.3 Molecular structure of silibinin where the OH groups relating to protolytic constants are shown.  
Acidity constants obtained by spectrophotometric measurements (by Hyperquad program) were in 
good agreements with constants determined by potentiometric method. 
 
 
Figure 2.4 UV-Vis spectra of a Sil-p-Man solution of 5.0 x 10-5 M to varying pH (from 2 to 11.1). 
CD-UV measurements in solution, at different pH, show variations in the CD spectrum that follow the 
same changes registered in UV-Vis spectra. 
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Figure 2.5 CD-Vis spectra of the glyco-conjugate Sil-p-Man, concentration of 5.0 x 10-5 M to vary pH from 2 to 11.1. 
The electrochemical oxidation of flavonoids has been investigated using cyclic voltammetry (CV). All 
the above studies were based on in situ analyses using glassy carbon electrodes. Silibinin (1) and glyco-
conjugates (14−19) are subjected to a single oxidation. This peak around 0.7 V (v.s. a saturated  silver 
chloride reference electrode) appears in all the compounds under study and its anodic currents are 
probably associated with oxidation involving the OH group on C-4" (as Gyorgy el al. reported for 
silibinin)31. Cyclic voltammograms for silibinin gluco-conjugate Sil-p-Man, recorded at different pH, 
are reported in Figure 2.6. 
Peak oxidation potential (EP) and half-peak oxidation potential (EP/2) are deducing from 
voltammograms. The number of electrons, ne, involved in the process are obtained by equation: 
EP - EP/2 = 56.5 mV/ne, 
The value of EP - EP/2 in the range pH 3.0−7.0, is (37 r 8) mV, which corresponds to ne | 1.6      
(probably two electrons involved). 
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Figure 2.6. Cyclic voltammogramms for Sil-p-Man recorded at different pH (from 3 to 9) (scan rate 50mV/s) 
 
The reducing properties of compounds are very often characterized by formal redox potentials E°’, 
determinated at pH = 7.0 (v.s. saturated silver chloride reference electrode). This parameter can be 
obtained by half-wave potential (E1/2), which is related to EP/2 from equation: 
 
 E1/2 = EP/2 - 28 mV/ne 
 
The results are presented in Table 2.8.   
 
Table 2.8 Formal redox potentials at pH = 7.0 (v.s. saturated silver chloride reference electrode), for some silibinin 
glyco-conjugates. 
Compound Silibinin Sil-p-Glc Sil-p-Man Sil-p-Gal  Sil-p-Lact 
E°’, Volt 0.65 ± 0.1 0.67 r 0.02 0.64 r 0.02 0.69 r 0.02 0.68 r 0.02 
 
The electrochemical behavior is dependent on pH (Figure 2.7). The slope of Ep/2 vs pH is (33 r 8) 
mV, corresponding at two protons involved in the oxidation. 
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Fig. 2.7 Ep/2 values (mV, v.s. saturated silver chloride reference electrode) for Sil-p-Man determined over the pH range 
3.0−9.0. 
 
New glycosylated show a redox behavior similar to the silibinin and the acidic constants of the 
phenolic groups, very often implicated in the complexation with metals such as (Cu, Zn, Fe). 
 
In conclusion, new silibinin glyco-phosphodiester conjugates were synthesized and their biological 
and electrochemical investigation were evaluated. Their synthesis was successfully realized in a short 
time and in very good yields. The serum stability of the new conjugates was evaluated, as well as their 
redox behavior was studied with different approaches. Infact, new derivatives were subjected to DPPH 
free radical scavenging assay in preliminary study to evaluate their antioxidant activities. Irrespective 
of the sugar moiety examined, all compounds exhibited a radical scavenging activities slightly higher 
than to silibinin. In the other hand, the new derivatives showed a water solubility well above that of 
silibinin, in fact it was possible to prepare solutions of about 70 mg/mL of analogues in water. 
Moreover, their acidity and redox capacity have been evaluated by potentiometric and voltammetric 
studies. The glyco-conjugation by phosphodiester bond has been to improve the water solubility of 
silibinin core without making any changes to the behavior redox. In collaboration with Prof. 
Pannecouque of Rega Institute of Leuven (Belgium) and prof. Agarwal of Department of 
Pharmaceutical Sciences, University of Colorado, future studies are in progress to evaluate the antiviral 
and anticancer activity, respectively. 
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2.4 Dimeric phosphate-linked silibinins: synthesis, spectroscopic properties, solubility and 
radical scavenger ability 
 
Oxidative stress is a state present in all aerobic organisms. It occurs when the production of reactive 
oxygen species (ROS) exceeds the limited capacity of the cellular antioxidant system. ROS are small 
molecules, commonly produced in radical reactions, with the capacity to quickly interact with cellular 
structures. They are represented by various chemical entities: oxygen radicals (such as hydroxyl radical 
HO• and singlet oxygen 1O2) or nonradical substances (such as hydrogen peroxide H2O2). ROS are 
usually very reactive; they do not have long lifetimes and cannot be transported for long distances in an 
organism. They therefore damage the cell structures that are closest to the site of their formation. They 
readily attack nucleic acids, proteins, and lipids. The molecule that is attacked is either damaged, 
destroyed, or has its function altered. Oxidative stress plays a key role in the origin and development of 
many diseases connected with inflammation, such as neurodegeneration, cardiovascular diseases, and 
cancer.  
Free radicals are molecules containing unpaired electrons, which makes them very reactive. This 
reactivity leads to donating or accepting electrons from surrounding molecules to achieve a more stable 
state. The reaction of such a radical with a nonradical causes a radical chain reaction and creates new 
radicals, which, in turn, react with other molecules. This process is called propagation. The reaction is 
terminated when two radicals react with each other to form a nonradical. Hydroxyl radical is the most 
potent oxidant and one of the most reactive natural free radicals known. It has a very short half-life and 
thus reacts with molecules at the site of its formation. The reaction rate with other molecules is high, 
approximately 109 to 1010 M1 × s−1. 
As can be expected from the enormous reactivity of HO•, the exposure of DNA (or RNA) to it yields a 
large number of products. To prevent or overcome the damage to biomolecules and pre- vent the 
development of the diseases previously mentioned, the cells take advantage of various ways and 
enzymatic systems. Sometimes, the capacity of the endogenous enzymes and antioxidants is 
overwhelmed. For these cases human cells may use exogenous antioxidants supplied in the diet, such 
as vitamins, carotenoids, and flavonoids, such as polyphenols. Polyphenols are widely distributed in 
nature and are, in many cases, the active compounds of the medicinal plants from which they can be 
isolated. Despite the few and common biosynthetic origins, polyphenols encompass many subclasses of 
structurally diverse entities and from the different pharmacological properties. Many studies suggests 
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that the mechanisms by which plant polyphenols exert their protective actions against cardiovascular 
and neurodegenerative diseases, as well as cancer and diabetes, are not simply due to their redox 
properties, but rather to their ability to directly bind to bio-targets (peptides, proteins, nucleic acids).  
It is the task of scientists to develop suitable methods for determining the antioxidant activity and to 
search for new antioxidants in natural sources. There are various ways of measuring the scavenging 
activity of HO• and 1O2. The choice of method substantially influences and determines the results. 
Obviously, we cannot expect the same results for all of the different methods used to measure ROS 
scavenging in antioxidant activity assays of flavonoids. Basically, there are 2 main steps in the 
procedure of ROS-scavenging methods: (1) production of ROS: this includes, in the case of HO•, the 
employment of various physical processes, such as pulse radiolysis, γ -irradiation, or UV photolysis of 
H2O2, and also different chemical reactions, among which the most widely used is the Fenton reaction; 
(2) reaction of ROS with a suitable probe and the consequent detection of a reaction product or 
corresponding change in some physical parameter. Because HO• is a very reactive substance, it is not 
possible to measure its presence and concentration directly; but the first reaction of HO• with another 
molecule, a probe or trap, followed by the detection of a reaction product is crucial.32  
Recently we reported the synthesis of new silibinin conjugated by phosphodiester bond with a mono- 
and di-saccharides in the position 9". The presence of carbohydrate moiety and phosphate group 
increase the water solubility of the aglycon and brings the possibility of prodrug approach making 
possible the improvement of the its pharmaceutical, pharmacokinetic and/or pharmacodynamic 
properties. New derivatives showed a better solubility in water while maintaining a good antioxidant 
activity compared with that of the silibinin. 
As a part of our continuing research effort towards the synthesis of new natural product analogues 
exploiting the phosphoramidite chemistry, we present here the efficient synthesis of new dimeric 
linked-phosphate silibinins and the related study of redox behavior. In order to achieve a more 
complete picture of spectroscopic properties, solubility and radical scavenger ability, we have studied 
the silibinin dimers in collaboration with Marcello Brigante, Maitre de Conférences at Université 
Clermont Auvergne, Institut de Chimie de Clermont-Ferrand (ICCF), Equipe Photochimie (France). 
Notably, during the period that I spent in the Brigante’s group, I performed analysis to characterize 
spectroscopically the dimers in comparison with silibinin and assess their reactivity against some 
oxygen free radicals. 
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Exploiting the selective protection to hydroxyl groups of the silibinin we have developed an efficient 
strategy for the synthesis of new 3-9", 3-3 and 9"-9" dimers of silibinin (Scheme 2.5) in good yields. 
 
 
Scheme 2.5 Synthetic strategy for the new 3-9", 3-3 and 9"-9" dimers of silibinin. 
Solubility in water of silibinin and dimers as well as their ability to react with reactive oxygen species 
(ROS) were determined. Reactivity with ROS was quantified by estimating their second order rate 
constant with singlet oxygen and hydroxyl radical in solution. For this purpose, 545 nm centered 
excitation of Rose Bengal (RB) and laser flash photolysis (LFP) experiments were coupled with a 
kinetic competition approach. Laser Flash Photolysis is used for a kinetic study of short lived species, 
and was developed by George Porter and Ronald Norrish (Nobel Prize 1967). This technique provides 
direct transient measurement of reactions involving species such as radicals or excited states. In LFP 
the sample is firstly excited by a strong pulse of monochromatic light from a laser of a nanosecond 
pulse width. This first pulse starts a chemical reaction or leads to an increased population for energy 
levels other than the ground state within a sample of atoms or molecules. Differences in absorption 
compared to the ground state are measured with time resolved spectroscopy.  
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Silibinin is a flavonolignan with five hydroxy groups (three phenolic, one secondary and one primary) 
with a different reactivity. To obtain the suitable building blocks 2 and 3 (Scheme 2.6) we have 
developed a regioselective protection of the different hydroxyl functions with isobutyryl chloride e in 
THF dry at low temperature. The desired compounds 2 and 3 were obtained with a 15 and 28% of 
yields, respectively. 
 
Scheme 2.6  Silibinin building blocks and their corresponding phosphoramidites. (a) isobutyryl chloride, TEA, THF dry (b) 
2-cyanoethyl-N,N-diisopropylamino-chlorophosphoramidite, DIEA, DCM dry, r.t. 
In order to prepare the corresponding phosphoramidites, we converted 2 and 3 (Scheme 2.6) into the 
phosphoramidites 4 and 5 by a classic reaction with 2-cyanoethyl-N,N-diisopropylamino-
chlorophosphoramidite. After work-up the silica gel chromatography afforded desired compounds 4 
and 5 in a 65% yields. The identity of compounds 2−5 was confirmed by NMR (1H, 13C and 31P) and 
ESI-MS data. Compounds 2 and 3 were coupled, in the three different provisions (Scheme 2.7), with 
phosphoramidites 4 and 5 using 0.45 M 4,5-dicyanoimidazole (DCI) in ACN. After oxidation treatment 
with 5.5 M tert-butyl hydroperoxide solution in decane, the crude material was purified by gel 
chromatography. Several complex fractions were recovered by gel chromatography, but only those 
with the signal 31P NMR active, were treated with conc. aq. ammonia and MeOH (1:1, v:v) at 50 °C, 
allowing full deprotection from isobutyryl and cyanoethyl groups. After RP-18 HPLC purification the 
products were converted into the corresponding sodium salts by cation exchange on a DOWEX (Na+ 
form) resin, leading to the desired phosphodiester derivatives 6−8 in good yields (50, 45 and 60 % 
respectively, Scheme 2.7). 
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Scheme 2.7 Phosphodiester silibinin dimers derivatives. 
Given the very complex mixture (there are at least three diastereoisomers for each dimer) the NMR 
analysis was not possible. The products obtained by cation exchange were suspended in DMSO-d6, but 
the goodness of NMR spectra did not allow a detailed assignment of different spin systems. The 
structures of 6−8 were confirmed by 31P NMR and MALDI-MS analyses. 
In order to evaluate their antioxidant activity, all silibinin dimers were subjected to 2,2-diphenyl-1-
picrylhydrazyl free radical scavenging assay.18 The DPPH test is the non-enzymatic method currently 
used to provide basic information on the scavenging potential of stable free radicals in vitro.  From the 
DPPH assay shown in Table 2.8, we observed that conjugating two moieties of silibinin did not led to a 
significant reduction of quenching properties. For comparison purposes, the antioxidant activities of 
quercetin were evaluated as controls. In particular the new silibinin dimers 6−8 showed DPPH radical 
scavenging activities higher to that of the silibinin, confirming that the introduction in 9'' of the moiety 
did not influence the radical scavenging activity of this metabolite.22, 23  
Blood and extracellular fluid contain a large number of hydrolytic enzymes, such as cholinesterase, 
aldolase, lipase, dehydropeptidase, alkaline and phosphatase. Several functional groups, such as ester, 
amide, carbamate, lactam, lactone, sulphonamide and, of course, phosphate, are susceptible to plasma 
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degradation. If the new compound has affinity for one of these enzymes and it has a hydrolyzable 
group in the right position, it can be decomposed in the plasma. 
Hydrolysis in plasma can be a major cause of compound clearance, and pharmacologically 
efficacious concentrations may not be achievable in vivo pre-clinical study. Since the presence of a 
junction of phosphodiester type, which could be susceptible to the action of endogenous phosphatase 
before the active complex can reach its molecular target, the stability of the new synthesized conjugates 
was evaluated in human serum, and monitored over time by of HPLC analysis. New dimeric 
phosphate-linked silibinins (6−8) were incubated at 37 °C with human serum from human male AB 
plasma in Tris•HCl buffer (pH = 8.0 containing 10 mM MgCl2). Small aliquots of the mixture were 
taken at defined time intervals, kept at 85 °C for 5 min, equilibrated at rt, and analyzed by HPLC on an 
RP column. As shown in Table 2.8 the dimers 6−8 are degraded with a time half-lives of 81 to 87 
hours. 
 
Table 2.8 Summary table of MALDI analysis, HPLC retention times, IC50 and serum half lives for compound 6−8. 
 MALDI tR (min) DPPH IC50(mM) t1/2 (hours) 
6 calcd for C50H43O22P = 1026.20 
found [M-H]- = 1025.79; [MNa-H]- = 1047.25 
17.32 0.99 ± 0.04 86.7 
7 calcd for C50H43O22P = 1026.20 
found [M-H]- = 1025.11; [MNa-H]- = 1047.03 
17.24 0.63 ± 0.05 85.6 
8 calcd for C50H43O22P = 1026.20 
found [M-H]- = 1025.66; [MNa-H]- = 1047.05 
17.17 0.99 ± 0.07 81.2 
Silibinin (1)   1.4 ± 0.06  
Quercetin   0.18 ± 0.01  
     
 
As reported the water solubility of silibinin change according to the experimental conditions such as 
pH and temperature.25,26 In this work we determined the solubility of the new dimers (6−8) and then 
compared to the water solubility of the silibinin (1). 
Solubility experiments were performed by dissolving selected compound in milli-Q water leaving that 
10 min under magnetic stirring in the dark. Molar absorption coefficients (ε) for each compound in 
water were determined from calibration curves (absorbance vs concentration) with successive dilutions 
of a stock solution using the Beer-Lamberts law. For silibinin, stock solution was prepared in CH3CN 
(1.18 mg in 1 mL) and absorption spectra were recorded by diluting silibin solution in H2O (2% of 
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CH3CN used to increase the solubility and, as consequence, quantification limit) UV-Vis spectra were 
presented in Figure 2.7 revealing the presence of absorption band centered around 288 corresponding 
to the π−π* transition and around 334 nm that should be also due to the transition n−π* on the oxygen 
of ketones groups. 
 
Figure  2.7. UV-vis spectra of Silibinin in H2O:CH3CN 98:2 solution and dimers in water at pH 6.5. 
 
Silibinin results only slightly dissolved when 0.5 mg were suspended in 10 mL of water and, after 
filtration, the absorption spectrum reveals a maximum at 288 nm with an absorption of ~ 0.018. The 
saturated concentration of silibinin in water was estimated to be 0.9 µM corresponding to ~ 0.44 mg L1.  
The solution was also keep in the dark and stirred during 12 hours without any significant solubility 
increase. 
In order to investigate the possible increase of solubility as function of pH, a phosphate buffer 
solution at pH 8.0 was prepared (buffer concentration of 1 mM) and 0.35 mg of silibinin is suspended 
in 15 mL. After 10 min of magnetic stirring followed by 0.45µm filtration, the UV-vis spectrum reveals 
the presence of two absorption maxima: the first at 288 attributed to the silibinin with an absorption of 
~ 0.02 (in agreement with solubility determination) and a second centered around 330 nm indicating 
the formation of degradation products of silibinin in alkaline solutions. 
Solubility experiments that are summarized in Table 2.9 indicate that dimers were completely dissolved 
(0.1 mg in 10 mL) in water and solubility can be estimated to be ≥ 19.5 µM corresponding to > 20 mg 
L1.  
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Table 2.9. Spectroscopic characteristics and solubility of silibinin and dimers in solution. *solution is saturated and 
suspension is filtered before analysis.  
Compound 288nmH  (M1 cm1) Suspended in 10 mL 
Theoretical 
concentration 
Abs288 nm after 
filtration 
Solubility in 
water 
1 22158 (CH3CN) 
19469 (H2O:CH3CN 9.8:0.2) 
0.44 mg 91.2 µM* 0.018 ≤ 0.9 µM 
6  9100 (H2O) 0.10 mg 19.5 µM 0.18 ≥ 19.5 µM 
7  14435 (H2O) 0.10 mg 19.5 µM 0.30 ≥ 19.5 µM 
8  18536 (H2O) 0.10 mg 19.5 µM 0.35 ≥ 19.5 µM 
 
 
Reactivity between silibinin and dimers with 1O2 and HO● was determined by use of Rose Bengal  
and hydrogen peroxide as respective ROS sources. For singlet oxygen, the steady-state concentration in 
solution ( ) in water is determined following tryptophan disappearance at different initial 
concentrations. The kinetic approach is summarized in reaction R5-R7 
 
 
    (R5) 
   (R6) 
  (R7) 
 
With the formation rate of  upon irradiation of RB, the pseudo-first decay of singlet 
oxygen in water (2.4 × 105 s1) and the second order rate constant between  and TRP (3.2 × 
107 M1s1).27 Application of the steady-state approximation to [ ] leads to the following equation: 
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data vs. different TRP concentrations can be fitted with a linear equation  lading to the 
quantification of singlet oxygen steady state concentration ( ) that is equal to the ration /
. 
Dimers reactivity toward singlet oxygen results to be closed to the value determined for silibinin (see 
dimer 6) or about 35% lower in the case of dimer 8 (Table 2.10). Second order rate constant fare in the 
same order of magnitude reported in literature for molecules with similar structure. Morales and co-
workers28 reported a reactivity ranging from 2.4 to 13.4 × 107 M-1 s-1 for flavonoid derivative such as 
quercetin and morin.  
 
Table 2.10 Singlet oxygen steady state concentrations [1O2]SS and second order rate constant ( 1
2 ,
II
O Xk ) between singlet 
oxygen and silibinin or dimers in THF and H2O solutions. 
Compound THF H2O 
 [1O2]SS (M) (M1s1) [1O2]SS (M) (M1s1) 
1 3.79 × 1013 6.1 ± 0.4 ×107 - - 
6  - - 4.07 × 1013 6.8 ± 1.2 × 107 
7  - - 4.07 × 1013 5.4 ± 0.3 × 107 
8  - - 4.07 × 1013 4.0 ± 0.2 × 107 
 
 
Experimental data like those reported in Figure 2.8 for dimers 7 and 8 (Abs/Abs0 followed at 475 nm 
vs dimer concentration) are fitted with a linear equation (E1) leading to the estimation of second order 
rate constant between hydroxyl radical and selected molecule. 
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Figure 2.8. Abs/Abs0 measured at 475 nm as function of dimers 6 and 7. The solid line represents the linear fit of the 
experimental data and dashed lines denote the 95% confidence interval of this fit. 
 
Estimation of second order rate constant indicates that the most reactive species are dimer 7 and 8 
with a second order rate constant ≥ 1.5 × 1010 M1 s1 (see Table 2.11 summarizing experimental results). 
Wang and co-workers29 investigated the reactivity of hydroxyl radical with phenolic compounds in 
order to estimate their antioxidative ability using aqueous pulse radiolysis. The value of 1.5 × 1010 M1 
s1 was found for quercetin that is closed to those estimates for green tea polyphenols. Interestingly, 
Husain at al.30 reported that reactivity of flavonoids toward photogenerated hydroxyl radical increases 
with the number of hydroxyl groups in the aromatic ring.  
 
Table 2.11: Second order rate constant ( ,
II
HO Xk x ) between hydroxyl radical and silibinin or dimers in H2O/CH3CN (9/1) 
solutions. 
Compound (M1s1) 
1 8.26 ± 1.64 × 109 
6  6.73 ± 0.32 × 109 
7  1.52 ± 0.08 × 1010 
8  ≥ 2.0 × 1010 
 
 
,
II
HO Xk x
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In conclusion, new dimeric linked-phosphodiester silibinins were synthesized and their biological and 
radical scavenger behaviour were evaluated. Exploiting our solution phase strategy, a variety of 
structurally diverse silibinin dimers were successfully realized in a short time and in very good yields. 
New derivatives were subjected to DPPH free radical scavenging assay in preliminary study to evaluate 
their antioxidant activities. Thanks to the conjugation through a phosphodiester junction of two units of 
molecule, all compounds exhibited radical scavenging activities quite higher than to silibinin. In the 
other hand, the new derivatives showed water solubility well above that of silibinin. Since the presence 
of a junction of phosphodiester type, which could be susceptible to the action of endogenous 
phosphatase before the active complex can reach its molecular target, the stability of the new 
synthesized conjugates was evaluated in human serum, and as shown in Table 2.8 the dimers (6−8) are 
degraded with a time half-lives of 81 to 87 hours and this makes them ideal candidates for further 
clinical trials. Moreover, for all the new analogues, their reactivity against some oxygen free radicals 
(1O2 and HO●) was investigated. Dimers reactivity toward singlet oxygen results to be closed to the 
value determined for silibinin. Second order rate constant fare in the same order of magnitude reported 
in literature for molecules with similar structure. These data encouraged our future studies aimed to 
improve the synthetic strategy to realize libraries of optically pure linked-phoshate silibinin dimers. 
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Chapter 3: Experimental Session  
3.1 New Silibinin glyco-conjugates: Synthesis and evaluation of antioxidant properties.  
3.1.1 General procedure for the synthesis of conjugates (6−9):   
Phosphoramidite 1 (150 mg, 0.18 mmol) and the select saccharide compound 2−5 (0.19 mmol, 
previously dried and kept under reduced pressure, were reacted with a 0.45 M tetrazole solution in 
anhydrous CH3CN (1.0 mL, 0.45 mmol). The reaction was left under stirring at room temperature and 
monitored by TLC in the eluent system n-hexane:AcOEt, (1:2, v:v). After 1 hour, a 5.5 M tert-butyl 
hydroperoxide (tert-BuOOH) solution in decane (70 μL, 0.40 mmol) was added to the mixture and left 
under stirring at room temperature. After 30 minutes the reaction mixture was diluted with CHCl3, 
transferred into a separatory funnel, washed three times with water and dried under reduced pressure. 
The next treatment with TEA/pyridine (1:1, v/v) to 1 hour at 50 °C and then with aq. ammonia 
(28%)/CH3OH (1:1, v:v) for 1 hour at room temperature, allowed full deprotection from acetyl and 2-
cyanoethyl groups. The dried mixtures were purified by a Sep-Pak C18 Cartridge and then converted 
into the corresponding sodium salts by cation exchange on a DOWEX (Na+ form) resin to have a 
homogeneous samples in good yield (60-72%). 
Compound 6 (brown powder, 88.1 mg, 68%): 31P NMR (161.98 MHz, D2O, room temperature, mixture 
of diastereoisomers) δ 2.9, 1.4, 0.8. HRMS (MALDI-TOF, negative ions) m/z calcd for C31H32O18P = 
723.1332, found 723.1332 [M  H]-. 
Compound 7 (brown powder, 94.0 mg, 72%): 31P NMR (161.98 MHz, D2O, room temperature, mixture 
of diastereoisomers) δ 1.3, 0.9, 0.7. HRMS (MALDI-TOF, negative ions) m/z calcd for C31H32O18P = 
723.1332, found 723.1333 [M  H]-. 
Compound 8 (brown powder, 82.3 mg, 63%): 31P NMR (161.98 MHz, D2O, room temperature, mixture 
of diastereoisomers) δ 2.4, 1.6, 1.1, 0.8. HRMS (MALDI-TOF, negative ions) m/z calcd for 
C31H32O18P = 723.1332, found 723.1333 [M  H]-. 
Compound 9 (brown powder, 104.8 mg, 60%): 31P NMR (161.98 MHz, D2O, room temperature, 
mixture of diastereoisomers) δ 1.1, 0.8. HRMS (MALDI-TOF, negative ions) m/z calcd for C37H42O23P 
= 885.1860, found 885.1859 [M  H]-. 
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3.1.2 DPPH radical scavenging activity assay  
 
The antioxidant activities of the compounds was assessed by examining their abilities to scavenge the 
1,1-diphenyl-2-picrylhydrazyl free radical. DPPH solution (20 mg/mL) was prepared in methanol. The 
compounds was dissolved in methanol to prepare the stock solution (1 mM). Freshly prepared DPPH 
solution was taken in test tubes and analogue solutions (1 mM−1 μM) were added to every test tube so 
that the final volume was 2.25 mL and after 10 min, the absorbance was read at 515 nm. Quercetin and 
2,3-dehydrosilybin were used as a reference standards and dissolved in methanol to make the stock 
solution with the same concentration (1 mM). 
3.1.3 Xanthine Oxidase Inhibition Assay.  
 
Oxidative stress was induced by incubating MKN28 cells with XO (10-100 mU/mL) in the presence of 
its substrate xanthine (X) (1 mM) for periods of up to 3 hours. We examined the effect of silibinin and 
of our analogues 6−9 on X/XO induced cell damage. In particular, cells were incubated with serum free 
medium (control) for 1 - 48 hours; with serum free medium for 148 hours and then with X (1 mM) XO 
(50 mM) for 2 hours (X/XO control); with 6−9 and silibinin (10−200 µM) for 148 hours and then, after 
washing, with X (1 mM)  XO (50 mM) for 2 hours. Subsequently, we determined cell viability by [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazoliumbromide] MTT assay in MKN28 cultured cells. 
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3.2 Synthesis, biological and electrochemical investigation of new silibinin glyco-
phosphodiester conjugates 
3.2.1 Synthesis of silibinin phosphoramidite building block 3 
Silibinin (1.6 g, 3.3 mmol) previously dried by repeated coevaporate with anhydrous THF, was 
dissolved in 8 mL of anhydrous pyridine and DMTCl (1.48 g, 4.37 mmol) was added. The mixture was 
kept at 50 °C for 3 hours. After monitoring by TLC, the reaction was stopped by addition of CH3OH 
and the mixture dried under reduced pressure. The crude material was purified by column 
chromatography with a gradient of n-hexane in CHCl3, from 10% to 0%, and then increasing the 
polarity eluting with CHCl3 and increasing percentages of CH3OH from 0% to 5%. In all of the eluants, 
it was used 0.5% of Et3N. The derivative 9"-ODMT was obtained in good yield. (2.5 g, 3.18 mmol, 
96%).  
9"-ODMT silibinin (2.5 g, 3.18 mmol) was dissolved in 8 mL of pyridine and isobutyric anhydride was 
added (6.5 mL, 60 mmol). The reaction mixture was kept under stirring for 2 hours at room 
temperature. After monitoring by TLC, the reaction was stopped by addition of CH3OH and then kept 
at 0 °C for 1 hour. The mixture was extracted with a saturated aqueous solution of NaHCO3 and CHCl3 
and the organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to 
lead 3,5,7,4"-tetra-O-isobutyryl-9"-O-DMT silibinin (2.70 g, 2.53 mmol, 79%). 
3,5,7,4"-tetra-O-isobutyryl-9"-ODMT silibinin (2.70 g, 2.53 mmol) was selectively deprotected from 
DMT group with a solution of HCOOH 5% in CH2Cl2 (150 mL). The reaction mixture was kept under 
stirring for 1 hour at room temperature. After monitoring by TLC, the mixture was washed with a 
saturated aqueous solution of NaHCO3 and the organic phase was dried over anhydrous Na2SO4 and 
evaporated under reduced pressure. The crude material was purified by column chromatography eluting 
with a gradient of ethyl acetate in hexane from 50% to 70% to obtain the compound 2 in good yield 
(1.5 g, 2.05 mmol, 81%). 
To 3,5,7,4"-tetra-O-isobutyryl silibinin (240.0 mg, 0.33 mmol) dissolved in anhydrous CH2Cl2 (5 mL), 
DIEA (390 μL, 2.22 mmol), and 2-cyanoethyl-N,N-diisopropylamino-chlorophosphoramidite (107 μL, 
0.48 mmol) were mixed. After 30 min the solution was diluted with EtOAc, and the organic phase was 
washed twice with brine and then concentrated. Silica gel chromatography of the residue (eluent n-
hexane:EtOAc, 3:7, v/v, in the presence of 1% of Et3N), afforded desired compound 3 (205.0 mg, 0.24 
mmol) in a 65% yield. 
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3.2.2 General procedure for the synthesis of monosaccharide building blocks 8−12 
 
Different 1-O-methyl-mono- and di-saccharides (Glc, Man, Gal, GlNAc, Thre, 2.07 mmol), previously 
coevaporated with anhydrous pyridine, were dissolved in anhydrous pyridine (8 mL) and reacted with 
DMTCl (1.86 mmol). The reaction mixture was stirred at room temperature for 2 hours (checked by 
TLC analysis) then quenched with MeOH and evaporated to dryness. The residue was extracted with 
CHCl3, the organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. 
The crude material was purified by column chromatography (98:2 chloroform/methanol with 0.5% of 
pyridine), leading a good yield of the 6-O-DMT glycosides (55-85%). Then, the 6-O-DMT-1-O-
methyl-glycoside (1.45 mmol) was solubilized in anhydrous pyridine (2 mL), and to the resulting 
mixture was added acetic anhydride (1.3 mL, 14 mmol). The mixture was stirring at room temperature 
for 12 hours (checked by TLC analysis). The reaction was quenched with MeOH at 0 °C and washed 
with CHCl3, the organic phase was dried over anhydrous Na2SO4 and concentrated under reduced 
pressure. Subsequently, we proceeded to remove the DMT group of full protected 1-O-methyl-
glycoside (1.45 mmol) with a solution of HCOOH 5% in CH2Cl2 and triisopropylsilane (1.45 mmol) 
under stirring at 0 °C. 
On completion of reaction, the resulting mixture was diluted with CH2Cl2 and washed with a saturated 
aqueous solution of NaHCO3. The combined organic layers were dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. The crude material was purified by column chromatography 
(chloroform/methanol, 98:2, v:v), leading the compounds 8−12 in good yields (55−65%). 
3.2.3 Synthesis of lactose building blocks 13 
Lactose octaacetate (1 g, 1.47 mmol) and I2 (523 mg, 2.06 mmol) were dissolved in anhydrous 
dichloromethane (10 mL). After completed dissolution, the reaction mixture was cooled to 0 °C and the 
Et3SiH (329 μL, 2.06 mmol) was added. After 5 minutes the reaction was refluxed until TLC analysis 
displayed complete consumption of the peracetylated sugar (the glycosyl iodides are partially unstable 
on TLC). The mixture was cooled to RT and then diluted with CH2Cl2. The organic phase was washed 
with a 5% solution of NaHCO3 containing Na2S2O3 (to remove residual amounts of iodine). The 
aqueous phase was re-extracted with CH2Cl2, and the combined organic layers were dried over 
anhydrous Na2SO4 and concentrated under reduced pressure. The glycosyl iodide intermediate was 
obtained in good yield (1.01 g, 1.3 mmol, 90%). 
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A mixture of appropriate glycosyl iodide (1.01 g, 1.3 mmol) and Ag2CO3 (69 mg, 0.65 mmol) was 
stirred at room temperature in anhydrous MeOH (20 mL) in presence of 3-Å molecular sieves for one 
day. On completion of the reaction (checked by TLC analysis), the mixture was filtered with CHCl3, 
concentrated under reduced pressure and directly deprotected with a solution of MeOH/NH4OHaq (1:1, 
v:v) for 30 minutes. The mixture was purified by column chromatography (chloroform/methanol, 9:1) 
to give the pure product β-1-O-methyl-lactoside (454 mg, 1.27 mmol, 98%). 
The methyl lactoside (454 mg, 1.27 mmol) was subsequently dissolved in anhydrous pyridine (8 mL) 
andreacted with DMTCl (386 mg, 1.14 mmol). The reaction mixture was stirred at room temperature 
for 2 hours, then quenched with CH3OH and evaporated to dryness. The residue was extracted with 
CHCl3, the organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. 
The 6-O-DMT-β-1-O-methyl-lactoside was purified by column chromatography (9:1 
chloroform/methanol with 0.5% of pyridine) (343 mg, 0.52 mmol, 41%). 
Subsequently, 6-O-DMT-β-1-O-methyl-lactoside (343 mg, 0.52 mmol) was fully acetylated with acetic 
anhydride (4 mL, 42.3 mmol) in anhydrous pyridine (8 mL) for 12 hours. The reaction mixture was 
quenched with MeOH and then washed with CHCl3, the organic phase was dried over anhydrous 
Na2SO4 and concentrated under reduced pressure. Finally, the fully acetylated 6-O-DMT-β-1-O-
methyl-lactoside was regioselectively deprotected from DMT group at the position 6 of the galactosyl 
residue with a solution of 5% HCOOH in CH2Cl2 and triisopropylsilane (1 mmol) under stirring at 0 °C 
for 1 hour. The reaction mixture was diluted with CH2Cl2 and washed with 5% of NaHCO3 aqueous 
solution and finally with H2O. The combined organic layers were dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. The product 13 was obtained in pure form and in good yield (196 
mg, 0.32 mmol, 61%) by column chromatography (chloroform/methanol, 9:1). 
 
3.2.4 General procedure for the synthesis of silibinin phosphodiester glyco-conjugates (14−19) 
 
The coupling reaction between the phosphoramidite and the mono and disaccharides appropriately 
protected was carried out by suspending the derivatives 7−12 (0.6 mmol) in a solution of DCI in 
acetonitrile (0.45 M, Activator 42®) and by adding 3-Å molecular sieves. After few minutes, the 
mixture was added to the silibinin phosphoramidite (0.54 mmol) and was kept under stirring for 1 hour. 
On completion of reaction monitoring by TLC analysis, tert-butyl hydroperoxide solution in decane 
(5.5 M) was added and after 30 minutes, the solvent was removed under vacuum and the crude material 
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was purified by column chromatography (chloroform/methanol, 99:1, 95:5). The products obtained 
were subsequently subjected to treatment with ammonia aqueous solution and methanol (1:1, v/v) at 
25 ° C for 3 hours for the full deprotection of protecting groups.  
After the deprotection treatment, the crude material was purified by reverse phase HPLC using a 
Phenomenex Luna® C18 column eluted with ammonium acetate 0.1 M with a linear gradient 20-100% 
ACN in 50 minutes (flow = 7 mL/min). Then, the material was desalted on Chromafix® C18 column 
(deionized H2O/CH3OH, 8:2, 1:1, CH3OH) and converted into the corresponding sodium salt by cation 
exchange on DOWEX resin (Na+) leading the compounds 14−19 in good yields (45−60 %). 
3.2.5 Analysis to serum stability of silibinin glyco-conjugates 
 
Reactions (500 PL reaction volume) were performed in 50 mM Tris•HCl pH 8.0 containing MgCl2 (10 
mM), silibinin conjugates (50 PL vol of a 10 PM solution), and human serum from human male AB 
plasma (400 PL). All reactions were incubed at 37 °C. From this solutions were taken samples of 
constant volume at different times, and the HPLC profile was analyzed in comparison with that of the 
intact compound. 
3.2.6 DPPH radical scavenging activity assay  
 
The antioxidant activities of the compounds was assessed by examining their abilities to scavenge the 
1,1-diphenyl-2-picrylhydrazyl free radical. DPPH solution (20 mg/mL) was prepared in methanol. The 
compounds was dissolved in methanol to prepare the stock solution 2 mM). Freshly prepared DPPH 
solution was taken in test tubes and analogue solutions (2 mM−5 μM) were added to every test tube so 
that the final volume was 2.25 mL and after 10 min, the absorbance was read at 515 nm. Quercetin and 
Trolox were used as a reference standards and dissolved in methanol to make the stock solution with 
the same concentration (2 mM). 
3.2.7 Citotoxicity on on human liver cancer cell (Hep G2) 
 
Silibinin and its new glyco-conjugates were solubilised in DMSO at a final concentration of 13.5 mM 
and then diluted in water to obtain the operational concentrations to be used for the tests on cells. 
Cytotoxic activity of different amounts of silibinin or its derivatives (0.3, 3 and 30 μM) was measured 
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at different incubation times (24, 48 and 72 hours) by a colorimetric assay. As a control, cell viability 
was assessed in the absence of the effectors.  
 
3.2.7 Determination of the acidity constants by potentiometric titrations, UV-Vis 
spectrophotometric measures and Circular Dichroism (CD-UV) of silibinin solutions. Redox 
behaviour carried out by cyclic voltammetry 
 
In according to the chemical structure of the molecule, silibinin shows many OH groups, that are 
ionizable. The acid-base behavior can be represented by general equilibria: 
H4-nL1-n + H2O  H3-nL1-n + H3O+   KAn                        (3.1) 
The study is conduced by potentiometric methods at 25 qC in 0.1 M NaClO4 as ionic medium. The 
measurements are carried out as potentiometric titrations where the hydrogenionic concentration is 
determined by the e.m.f. of cell (A): 
() RE/Test Solution/GE (+)               (A) 
in which GE symbolizes glass electrode and RE is the reference halfcell: 
RE = 0.1 M NaClO4/0.01 M AgClO4, 0.09 M NaClO4/AgCl/Ag 
The test solution has the general composition: 
CL M L, CA M HClO4, CB M NaOH, (0.1  CA) M NaClO4 
CHnL is chosen to be from 2.0 x 103 M to 8.0 x 103 M for silibinin glyco-conjugates (for silibinin the 
range is 2.0 ≤ CL≤ 6.0103 M, with 50% oh CH3OH), whereas (CA  CB) = CH is varied into 1.0 x 
103 M  9.0103 M. The e.m.f. of cell (A) at 25 °C may be written as: 
E = E0  0.05916 x log([H+]yH) + EJ     (3.3) 
where E0 is a constant in each titration, yH is the activity coefficient of the H+ ion and EJ represents the 
liquid junction potential at the test solution 0.1 M NaClO4 boundary.1 
It depends on the hydrogen ions concentration in the equation: 
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EJ =  0.35 x h        (3.4) 
Activity coefficients tend to 1 and EJ tend to 0 as the composition of test solution approaches 0.1 M 
NaClO4.  
Each titration consists of two parts. In first, E is measured in the absence of silibinin, or its conjugates, 
and (CA  CB) = [H+] is varied between 2 x 103 M and 5 x 105 M. From these data E0 values constant 
to within r 0.05 V is calculated, assuming EJ = 0.51 x [H+] + 0.24 x Kw[H+]1. In the second part, in 
the presence of ligand, acid-base behavior is followed by alcalification and/or acidification. 
Placing: 
EG0 = EG0’ + 0.05916 x log yH 
The equation (3.3) takes the form: 
EG = EG0 + 0.05916 x log h + EJ   (3.5). 
From experimental data (CL, CHnL, [H+]) the average number of protons (ZH) released per L molecule is 
evaluated by: 
ZH = ([H+]  CH  Kw/[H+])/CHnL                         (3.6) 
where a value  Kw = 1013.78 was utilized.   
Bringing ZH as function of pH the experimental data are in agreement with the solid line obtained with 
three equilibria.  
A speciation model was obtained by processing the experimental data using Hyperquad program.2 
The criterion used is to determine the values of the constants that make KAn minimize the sum U of 
squared weighted residuals: 
U EG,i exp  EG,i calc)2                   (3.7) 
where, for the i-th measurement, EG,i exp and EG,icalc represent, respectively, the experimental potential 
and that calculated for a set of constant value KAn.. 
The minimum of the function U is found by the method of Newton-Raphson. Once the minimum of U, 
Umin, the agreement between the experimental and calculated data is given by the variance σ2 defined 
as: 
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σ2 =   Umin/(n  m)                     (3.8) 
where n represents the number of experimental data and m is the number of KAn constants. 
The constants standard deviations are obtained by the diagonal elements of the variance-covariance 
matrix, calculated according to the equation: 
Mv = σ2 H1                                 (3.9) 
where H is the matrix of the normal equations and it is a square matrix of order m. 
The acid-base properties of the silibinin and its glyco derivatives are studied also by UV-VIS 
spectrophotometric procedures, that confirm the results obtained by potentiometric measurements. The 
experimental data collected are processed by the numerical minimization program Hyspec, Hyperquad 
package, which minimizes the standard deviation between the measured absorbance and those 
calculated by the proposed model constants. The results obtained are in agreement with those obtained 
from the potentiometric. Also, circular dichroism (CD-UV) of silibinin solutions were made. 
Measurements in solution, at different pH, show variations in the CD spectrum that follow the same 
changes registered in the UV-VIS spectra. For the voltammetric measurement, a polarograph Varian 
767 METROM it was utilized, with a measurement electod in glassy carbon, auxiliary electrode in Pt 
and a reference electrode of Ag/AgCl(s). 
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3.3 Dimeric phosphate-linked silibinins: synthesis, spectroscopic properties, solubility and 
radical scavenger ability 
3.3.1 Chemicals 
 
Silibinin is purchased from Sigma-Aldrich. HPLC grade MeCN, MeOH are purchased from Carlo 
Erba Reagents and Sigma-Aldrich. Hydrogen peroxide (30 %), from Fluka. Unless otherwise indicated, 
other chemicals are obtained from Sigma Aldrich and purity is > 98 %. 
Fresh aqueous solutions of H2O2, Rose Bengal and tryptophan are prepared before each experiment. 
The concentration of the stock solution of H2O2 in milli-Q water (Laser flash photolysis experiments) is 
determined using a molar absorption coefficient of 38.1 ± 1.4 M1 cm1 at 240 nm.9  
3.3.2 General methods 
 
Reactions for dimers’ synthesis are monitored by TLC (precoated silica gel plate F254, Merck) and 
Column chromatography: Merck Kieselgel 60 (70-230 mesh). The analysis is performed with a 
Shimadzu LC-8A PLC system equipped with a Shimadzu SCL-10A VP System control and Shimadzu 
SPD-10A VP UV-VIS Detector. HPLC purifications are carried out on Phenomenex RP18 column (5-
μm particle size, 10.0 mm × 250 mm i.d.) using a linear gradient of ACN in 0.1 M TEAA in H2O, pH 
7.0 from 5% to 100% over 30 minutes at a flow rate of 1.5 mL/min with detection at 260 nm. 
For the ESI MS analyses, a Waters Micromass ZQ Instrument  equipped with an Electrospray source, 
is used. MALDI TOF mass spectrometric analyses are performed on a PerSeptive Biosystems Voyager-
De Pro MALDI mass spectrometer. 
Absorption spectra are measured with a Varian Cary 100 Scan UV-vis spectrophotometer using 1 cm 
pathlength quartz cell. 
3.3.3 Synthesis of silibinin building block 2 
 
Silibinin 1 (1.5 g, 3.1 mmol) previously dried by repeated coevaporate with anhydrous THF and then 
was dissolved in 8 mL of anhydrous THF and TEA (2.1 mL, 15.4 mmol). Isobutyryl chloride (0.980 
mL, 9.3 mmol) was added and the mixture was kept at 0 °C for 30 minutes. After monitoring by TLC, 
the reaction was stopped by addition of MeOH and the mixture was extracted with CH2Cl2. The 
organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure, the crude 
material was purified by column chromatography (CHCl3/acetone, 96:4, v/v). The derivative 3,5,7,4"-
tetra-O-isobutyryl silibinin was obtained as pale amorphous solid (0.365 g, 0.47 mmol, 15%). 
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2 Rf = 0.6 (benzene/AcOEt, 80:20, v/v). 1H NMR (CDCl3, 400 MHz, room temperature, mixture 
of two diastereoisomers): δ = 7.15−6.96 (complex signals, 6H, H-2', H-5', H-6', H-2'', H-5'', H-6''), 6.77 
(complex signal, 1H, H-8), 6.58 (s, 1H, H-6), 5.71 and 5.69 (d, 1H, J = 12.2/12.3 Hz, H-3), 5.38 (m, 
1H, H-2), 5.08 and 5.06 (d, 1H, J = 8.3/8.7 Hz, H-7"), 4.04 (m, 1H, H-8''), 3.88−3.83 (overlapped 
signals, 4H, OCH3, H-9''a), 3.58 (dd, 1H, J = 3.2 Hz, J = 12.0 Hz, H-9''b), 2.98-2.74 (complex signals, 
3H, CH of isobutyryl groups), 2.62-2.52 (m, 1H, CH of isobutyryl group), 1.41−1.25 (m, 18H, CH3 of 
isobutyryl groups), 1.15−1.10 (m, 6H, CH3 of isobutyryl group) ppm. 13C NMR (CDCl3, 100 MHz, 
room temperature, mixture of diastereoisomers): δ = 185.0, 175.2, 175.1, 175.0, 174.1, 162.5, 162.4, 
156.5, 151.7, 151.6, 144.0, 144.1, 143.7, 140.6, 134.5, 128.7, 123.1, 123.0, 121.0, 120.8, 119.8, 119.7, 
117.1, 117.0, 116.6, 116.4, 111.2, 111.1, 108.7, 81.1, 81.0, 78.3, 78.4, 76.0, 75.9, 72.9, 72.8, 61.5, 56.1, 
56.0, 34.3, 34.0, 33.7, 19.0, 18.8, 18.7, 18.6 ppm. ESI-MS (positive ions): m/z calculated for C41H46O14 
= 762.29; found: 763.84 [M-H]+. 
3.3.4 Synthesis of silibinin building block 3 
 
Silibinin 1 (1.0 g, 2.7 mmol) previously dried by repeated coevaporate with anhydrous THF, was 
dissolved in 8 mL of anhydrous THF and TEA (2.1 mL, 15.4 mmol) and isobutyryl chloride (1.1 mL, 
10.4 mmol) were added. The mixture was kept at 0°C for 30 minutes. After monitoring by TLC, the 
reaction was stopped by addition of MeOH and the mixture was extracted with CH2Cl2, the organic 
phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude material 
was purified by column chromatography (eluent CHCl3/acetone, 96:4, v/v). The derivative 5,7,4",9"-
tetra-O-isobutyryl silibinin was obtained as pale amorphous solid (0.447 g, 0.58 mmol, 28%). 
 
3 Rf = 0.9 (benzene/AcOEt, 80:20, v/v). 1H NMR (CDCl3, 400 MHz, room temperature, mixture 
of two diastereoisomers): δ = 7.21−6.98 (complex signals, 6H, H-2', H-5', H-6', H-2'', H-5'', H-6''), 6.76 
(complex signal, 1H, H-8), 6.59 (s, 1H, H-6), 5.07 (d, 1H, J = 12.8 Hz, H-2), 5.00 (d, 1H, J = 8.3 Hz, 
H-7"), 4.56 and 4.55 (d, 1H, J = 12.3/12.4 Hz, H-3), 4.44 (dd, 1H, J = 2.3 Hz, J = 12.9 Hz, H-9"a), 4.26 
(m, 1H, H-8"), 3.98 (dd, 1H, J = 2.3 Hz, J = 12.8 Hz, H-9"b), 3.86 (s, 3H, OCH3), 2.98-2.76 (complex 
signals, 3H, CH of isobutyryl groups), 2.61 (ept, 1H, J = 6.8 Hz, CH of isobutyryl group), 1.36 
(complex signals, 18H, CH3 of isobutyryl groups), 1.21 (m, 6H, CH3 of isobutyryl group) ppm. 13C 
NMR (CDCl3, 100 MHz, room temperature, mixture of diastereoisomers): δ = 191.2, 176.4, 175.0, 
174.9, 174.1, 163.1, 157.0, 151.7, 151.5, 144.0, 143.5, 140.8, 134.3, 129.3, 123.2, 121.4, 121.2, 119.8, 
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117.5, 117.4, 116.6, 116.5, 111.1, 110.9, 109.7, 108.9, 83.2, 76.2, 75.9, 75.8, 73.1, 73.0, 62.4, 56.0, 
34.3, 34.1, 34.0, 33.9, 19.0, 18.9, 18.7, 18.6 ppm. 
ESI-MS (positive ions): m/z calculated for C41H46O14 = 762.29; found: 763.66 [M  H]+. 
3.3.5 Synthesis of silibinin building block 4 
 
To 3,5,7,4"-tetra-O-isobutyryl silibinin 2 (240.0 mg, 0.33 mmol) dissolved in anhydrous CH2Cl2 (5 
mL), DIEA (390 μL, 2.22 mmol), and 2-cyanoethyl-N,N-diisopropylamino-chlorophosphoramidite 
(107 μL, 0.48 mmol) were mixed. After 30 min the solution was diluted with EtOAc, and the organic 
phase was washed twice with brine and then concentrated. Silica gel chromatography of the residue 
(eluent n-hexane/EtOAc, 30:70, v/v, in the presence of 1% of Et3N), afforded desired compound 4 
(205.0 mg, 0.24 mmol) in a 65% yield. 
 
4 Rf = 0.8 (n-hexan/AcOEt, 60:40, v/v). 1H NMR (CDCl3, 500 MHz, room temperature, mixture 
of four diastereoisomers): δ = 7.11−6.94 (overlapped signals, 6H, H-2', H-3', H-6', H-2'', H-5'', H-6''), 
6.76 (comkplex signals, 1H, H-8), 6.56 (s, 1H, H-6), 5.69 (x2), 5.68 and 5.67 (d, 1H, J = 12.2 Hz, H-3), 
5.38, 5.37 (x2) and 5.36 (d, 1H, J = 12.2 Hz, H-2); 5.03 (x2) and 5.01 (x2) (d, 1H, J = 7.2/7.5 Hz, H-
7''), 4.00- 3.51 (complex signals, 12H, OCH3, H-8'', H-9''a, H-9''b, OCH2CH2CN, N[CH(CH3)2]2 
OCH2CH2CN), 3.01−2.68 (m, 3H, CH of isobutyryl groups), 2.56 (m, 1H, CH of isobutyryl group) 
1.36−0.95 (complex signals, 36H, CH3 of isobutyryl groups, N[CH(CH3)2]2) ppm. 13C NMR (CDCl3, 
100 MHz, room temperature, mixture of diastereoisomers): δ = 185.0, 175.2, 175.1, 175.0, 174.1, 
162.5, 162.4, 156.5, 151.7, 151.5, 144.3, 143.5, 143.4, 140.5, 134.7, 128.3, 128.2, 123.0, 122.9, 121.0, 
120.9, 120.8, 119.9, 119.8, 119.7, 117.7, 117.5, 117.1, 116.4, 116.3, 111.5, 111.4, 111.3, 111.1, 111.0, 
110.8, 108.7, 81.2, 81.1, 76.2, 75.9, 75.8, 72.9, 72.8, 62.7, 62.5, 62.2, 62.0, 58.8, 58.6, 58.5, 58.3, 56.0, 
55.9, 53.4, 43.3, 43.2, 34.2, 34.0, 33.9, 33.6, 24.6, 24.5, 19.0, 18.8, 18.7, 18.6 ppm. 31P NMR (CDCl3, 
161.98 MHz): δ = 150.2, 149.8, 149.7 ppm. ESI-MS (positive ions): m/z calculated for C50H63N2O15P = 
962.40; found: 963.92 [MH]+. 
3.3.6 Synthesis of silibinin building block 5 
 
To 5,7,4",9"-tetra-O-isobutyryl silibinin 3 (240.0 mg, 0.33 mmol) dissolved in anhydrous CH2Cl2 (5 
mL), DIEA (390 μL, 2.22 mmol), and 2-cyanoethyl-N,N-diisopropylamino-chlorophosphoramidite 
(107 μL, 0.48 mmol) were mixed. After 1 hour the solution was diluted with EtOAc, and the organic 
phase was washed twice with brine and then concentrated. Silica gel chromatography of the residue 
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(eluent n-hexane/EtOAc , 3:7, v/v, in the presence of 1% of Et3N), afforded desired compound 5 (205.0 
mg, 0.24 mmol) in a 65% yield. 
 
5 Rf = 0.8 (n-hexan/AcOEt, 60:40, v/v). 1H NMR (CDCl3, 500 MHz, room temperature, mixture 
of four diastereoisomers): δ = 7.30−6.97 (overlapped signals, 6H, H-2', H-3', H-6', H-2'', H-5'', H-6''), 
6.73 (comkplex signals, 1H, H-8), 6.54 (complex signal, 1H, H-6), 5.02 (x2) and 5.01 (x2) (d, 1H, J = 
7.8/8.0 Hz, H-7"), 4.94 (d, 1H, J = 9.3 Hz, H-2), 4.43 (complex signal, 1H, H-3), 4.34 (complex signal, 
1H, H-9"a), 4.20 (complex signal, 1H, H-8"), 4.10−3.94 (complex signals, 1H, H-9"a), 3.86 (complex 
signal, 3H, OCH3), 3.54−3.34 (complex signals, 9H, H-9''b, OCH2CH2CN, N[CH(CH3)2]2 
OCH2CH2CN) 2.96−2.74 (complex signals, 3H, CH of isobutyryl groups), 2.65 (complex signal, 1H, 
CH of isobutyryl group), 1.40-1.10 (complex signals, 36H, CH3 of isobutyryl groups, N[CH(CH3)2]2) 
ppm. 13C NMR (CDCl3, 100 MHz, room temperature, mixture of diastereoisomers): δ = 189.0, 188.3, 
176.4, 176.3, 174.9, 174.2, 174.1, 162.3, 156.3, 156.1, 149.9, 143.9, 143.8, 143.4, 143.3, 140.8, 135.9, 
134.2, 129.5, 129.4, 129.3, 123.2, 121.7, 121.6, 119.7, 119.6, 117.8, 117.5, 117, 4, 117.3, 116.8, 116.6, 
111.3, 111.1, 111.0, 108.6, 83.1, 82.9, 76.2, 75.8, 75.6, 75.2, 62.4, 62.3, 59.7, 59.5, 58.5, 58.3, 56.0, 
43.5, 43.4, 34.2, 34.1, 33.9, 24.8, 24.7, 24.6, 24.2, 24.1, 19.0, 18.9, 18.8, 18.7, 18.6 ppm. 31P NMR 
(CDCl3, 161.98 MHz): δ = 153.2, 153.0, 152.3, 152.2 ppm. ESI-MS (positive ions): m/z calculated for 
C50H63N2O15P = 962.40; found: 963.43 [MH]+. 
3.3.7 Synthesis of dimeric phosphate-linked silibinins 6−8 
 
The coupling reaction between the phosphoramidites 4 or 5 and the suitable silibinin building blocks 2 
or 3 was carried out by suspending 240 mg (0.32 mmol) the derivatives 2 or 3 in a solution of DCI in 
acetonitrile (0.45M, Activator 42®) and by adding 3-Å molecular sieves. After few minutes, the 
mixture was added to 270 mg (0.28 mmol) of silibinin phosphoramidites 4 or 5 and was kept under 
stirring for 1 hour. On completion of reaction monitoring by TLC analysis, 150 PL of tert-butyl 
hydroperoxide solution in decane (5.5 M) was added and after 30 minutes, the solvent was removed 
under vacuum and the crude material was purified by column chromatography (eluent CHCl3/CH3OH, 
99:1 to 95:5, v/v). The material obtained were subsequently subjected to treatment with ammonia 
aqueous solution (28%) and methanol (1:1, v/v) at 50 °C for 3 hours for the full deprotection. After the 
deprotection treatment, the crude material was analyzed by RP-HPLC using a Phenomenex Luna C18 
(5 μm particle size, 10.0 mm × 250 mm i.d.) eluted with 0.1 M ammonium acetate with a linear 
gradient 20-100% ACN in 30 minutes (flow = 3.0 mL/min) and then purified by RP-HPLC using a 
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Gemini C18-110A preparative column (10 μm particle size, 250 mm × 21.2 mm i.d.) eluted with 0.1 M 
ammonium acetate with a linear gradient 20−100% ACN in 50 minutes (flow = 7 mL/min). The 
recovered material was desalted on Chromafix® C18 column eluted with H2O/CH3OH 8:2 (v/v) and 
converted into the corresponding sodium salt by cation exchange on DOWEX resin (Na+) leading the 
compounds 6 - 8 in good yields (50, 45 and 60 % respectively). 
3.3.8 HPLC purification of 6−8 
 
The sample solutions were prepared by dissolving and sonicating the accurately weighed compound (6 
- 8) in H2O/CH3OH (1:1, v/v). The obtained solution (ca 10 mg/mL) was then applied to Nylon filters 
(pore size = 0.45 µm) and then purified. 
The HPLC analysis was performed with a Shimadzu LC-9A system equipped with a Shimadzu SPD-
6A Detector using a RP18 column Phenomenex LUNA (5-μm particle size, 10.0 mm × 250 mm i.d.) 
and eluted with ammonium acetate 0.1 M with a linear gradient 20−100% ACN in 30 minutes (flow = 
1.5 mL/min). The chromatograms were monitored at 288 nm. 
The preparative HPLC method was performed with a Shimadzu LC-8A PLC system equipped with a 
Shimadzu SCL-10A VP System control and Shimadzu SPD−10A VP UV-VIS Detector. A 
Phenomenex Gemini C18-110A preparative column (10-μm particle size, 250 mm × 21.2 mm i.d.) was 
used and eluted with ammonium acetate 0.1 M with a linear gradient 20−100% ACN in 30 minutes 
(flow = 7 mL/min). The chromatograms were monitored at 288 and 254 nm. The HPLC system was 
controlled by LC Real Time Analysis software (Shimadzu Corporation). 
 
3.3.9 DPPH radical scavenging activity assay.  
 
The antioxidant activities of the compounds was assessed by examining their abilities to scavenge the 
1,1-diphenyl-2-picrylhydrazyl free radical. DPPH solution (20 mg/mL) was prepared in methanol. The 
compounds was dissolved in methanol to prepare the stock solution (2 mM). Freshly prepared DPPH 
solution was taken in test tubes and analogue solutions (2 mM−5 μM) were added to every test tube so 
that the final volume was 2.25 mL and after 10 min, the absorbance was read at 515 nm. Quercetin and 
Trolox were used as a reference standards and dissolved in methanol to make the stock solution with 
the same concentration (2 mM). 
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3.3.10 Serum stability 
 
Tests were performed in 500 PL of 50 mM Tris•HCl (pH 8.0 containing 10 mM MgCl2), 50 PL of 
dimeric phosphate-linked silibinin (10 PM solution), and human serum from human male AB plasma 
(400 PL). All reactions were incubed at 37 °C. From this solutions were taken samples of constant 
volume at different times, and the HPLC profile was analyzed in comparison with that of the intact 
compound. 
3.3.11 Singlet oxygen reactivity 
 
In order to estimate the reactivity of silibinin and dimers toward singlet oxygen, solutions are 
irradiated in a quartz cell of 1cm pathlength using 545 nm centered irradiation (1000 W Xenon lamp 
equipped with a monochromator) in the presence of 100 µM of RB as photosensitizer for singlet 
oxygen generation.3 An aliquot of solution was withdrawn at fixed interval time and analyzed by liquid 
chromatography  
Figure 3.1 shows absorption spectra of RB and overlap with emission spectrum reaching the solution  
recorded using a fiber optics coupled with a CCD spectrophotometer (Ocean Optics USD 2000+UV-
VIS). A reference lamp (DH-2000-CAL, Ocean Optics) is used for calibration.  
 
Figure 3.1 Emission spectrum reaching the solution (1000 W Xenon lamp equipped with a monochromator) and 
absorptions spectrum of 10µM RB solution. 
 
 86 
Silibinin is solubilized in THF, while dimers in H2O/CH3CN (9:1, v/v). THF and CH3CN are used as 
solvent to increase the silibinin and dimer solubility and due to their similar reactivity with singlet 
oxygen compared to the water (i.e. only limited singlet oxygen scavenging is accounted for by the 
solvent).4 Silibinin and dimers degradations are determined as following: an aliquot (200 µL) was taken 
at fixed interval times during irradiation, stored in the dark and monitored by ultra-high performance 
liquid chromatography, using a Waters Acquity UPLC instrument equipped with a diode array detector 
and a Waters 2695 separation module. 
The gradient is a linear increasing from 1% CH3CN and 99% water acidified with 0.1% of formic 
acid to 50% acetonitrile within 5 min. Then the CH3CN is increased linearly to 80% for 2 min and 
maintained constant for 2 min. The column is a Water Acquity UPLC C18 (100 mm × 2.1 mm × 1.7 
µm) and flow rate of 0.3 mL min‒N. Retention times of silibinin, 3-3, 3-9" and 9"-9" dimers are 5.4, 
6.3, 7.0 and 7.3 min respectively and detection wavelength set at 288 nm. 
The time evolution of silibinin and dimers in the presence of singlet oxygen could be fitted with a 
pseudo-first order equation 1 20 exp O
k t
tC C
 where C0 is the initial concentration of compound, Ct the 
concentration at time t and 1
2O
k the pseudo-first order degradation rate constant of target compound (X). 
The degradation rate ( dXR ) is determined as 1 2 0
d
X OR k C . 
The transformation rate of silibinin or dimers in the presence of singlet oxygen is given by the 
following relation: 1
2
1
2,
[ ] [ ]d IIX SSO XR k O X  where [ ]X  is the concentration of silibinin or dimers in 
solution. The second order rate constant between target molecule and singlet oxygen ( 1
2 ,
II
O Xk (M1 s1)) 
can be determined as: 1
2 1,
2[ ] [ ]
d
II X
O X
SS
Rk O X  
Singlet oxygen steady-state concentration [1O2]ss is quantified with tryptophan as probe using 
experimental conditions adopted for silibinin  and dimmers considering a second order rate constant 
between TRo and [1O2] of 3.2 × 107 M1 s1.10 
3.3.12 Hydroxyl radical generation and reactivity estimation 
 
Due to the high reactivity of THF with hydroxyl radical (~ 4.0 × 109 M-1 s-1),5 stock solutions of 
H2O2, SCN  , silibinin and dimers are prepared in Milli-Q water or CH3CN (for silibinin) and an 
appropriate volume is mixed just before each experiment, to obtain the desired concentration of all the 
species. Experiments in pure water are performed for dimmers while for silibinin, CH3CN/water (9:1, 
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v/v) solution is used. All experiments are performed at ambient temperature (295 ± 2 K) and in aerated 
solution. 
Hydroxyl radical are generated from 266 nm excitation of H2O2 solution, corresponding to the fourth 
harmonic of a Quanta Ray GCR 130-01 Nd:YAG laser system instrument, used in a right-angle 
geometry with respect to the monitoring light beam. The single pulse is of 9 ns in duration, and energy 
of 40 mJ. Individual cuvette samples (~3 mL volume) are used for a maximum of two consecutive laser 
shots to avoid degradation products formation and interferences. The transient absorbance at the pre-
selected wavelength is followed by a detection system consisting of a pulsed xenon lamp (150 W), 
monochromator and a photomultiplier (1P28). A spectrometer control unit is used for synchronising the 
pulsed light source and programmable shutters with the laser output. The signal from the 
photomultiplier is digitised by a programmable digital oscilloscope (HP54522A) and analysed using a 
32 bits RISC-processor kinetic spectrometer workstation.  
The UV-vis spectrum of HO● presents a maximum centered at 240 nm and direct quantification is 
difficult due to the low molar absorption coefficient (ε240nm) of ~ 600 M-1 cm-1.6 For this reason a 
kinetic approach based on the thiocyanate (SCN-) competition reactivity is generally adopted to 
estimate the second order rate constant of target compounds with HO ●  in solution based on the 
following equations: 
 
266
2 2 2
LFP nmH O HOxo    (R1) 
HO SCN HO SCNx   x o    (R2) 
2SCN SCN SCNx  x o    (R3) 
HO X productsx  o    (R4) 
 
The first step (R1) is the hydrogen peroxide photolysis using a laser pulse at 266 nm followed by the 
competition reactivity of generated HO● with SCN   (R2) and silibinin (or dimers) (R4). In the presence 
of high concentration of SCN  , thiocyanate radical ( SCN x ) reacts with another equivalent of 
thiocyanate to form di-thiocyanate radical anion ( 2SCN x ) (R3), which has a strong absorption molar 
coefficient at 475 nm (ε475nm = 7600 M-1 cm-1).7 
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The absorption of 2SCN x  in the presence of different concentration of HO● quenchers (X) allows the 
determination of the second order rate constant between hydroxyl radical and silibinin or dimers from 
the following equation: 
 
,0
,
[ ]
1
[ ]
II
HO X
II
HO SCN
k XAbs
Abs k SCN
x
x 
     (E1) 
 
in which Abs0 and Abs are the absorption of 2SCN x  transient followed at 475 nm without and with 
quencher respectively; 
,
II
HO SCNk x   is the second order rate constant between HO● and thiocyanate that is 
1.2 × 1010 M-1 s-1,8 [ ]SCN   is the initial concentration of thiocyanate (0.1 or 0.5 mM in our study); 
[ ]X  is the concentration of target compound and 
,
II
HO Xk x  the second order rate constant with hydroxyl 
radical.  
0Abs
Abs
 values vs concentration of quencher ([ ]SY ) can be fitted using a linear equation  y ax b   in 
which 0Absy Abs 
, 1,b  [ ]x X and ,
,
[ ]
II
HO X
II
HO SCN
k
a k SCN
x
x 
 . ,
II
HO Xk x value can be determined to be equal to
,
[ ]IIHO SCNa k SCNx 
u .  
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